US20060160103A1 - Mammalian neuralized family transcriptional regulators and uses - Google Patents
Mammalian neuralized family transcriptional regulators and uses Download PDFInfo
- Publication number
- US20060160103A1 US20060160103A1 US11/125,970 US12597005A US2006160103A1 US 20060160103 A1 US20060160103 A1 US 20060160103A1 US 12597005 A US12597005 A US 12597005A US 2006160103 A1 US2006160103 A1 US 2006160103A1
- Authority
- US
- United States
- Prior art keywords
- neu
- neu1
- proteins
- protein
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091007369 NEUR proteins Proteins 0.000 title claims abstract description 31
- 108091008023 transcriptional regulators Proteins 0.000 title description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 claims abstract description 36
- 239000011701 zinc Substances 0.000 claims abstract description 23
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 23
- 230000027455 binding Effects 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims description 57
- 238000013518 transcription Methods 0.000 claims description 18
- 230000035897 transcription Effects 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 abstract description 240
- 102000004169 proteins and genes Human genes 0.000 abstract description 184
- 238000000034 method Methods 0.000 abstract description 49
- 230000001105 regulatory effect Effects 0.000 abstract description 22
- 102000040430 polynucleotide Human genes 0.000 abstract description 21
- 108091033319 polynucleotide Proteins 0.000 abstract description 21
- 239000002157 polynucleotide Substances 0.000 abstract description 21
- 230000002103 transcriptional effect Effects 0.000 abstract description 18
- 239000013598 vector Substances 0.000 abstract description 18
- 108700026244 Open Reading Frames Proteins 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 177
- 102100022166 E3 ubiquitin-protein ligase NEURL1 Human genes 0.000 description 159
- 210000004027 cell Anatomy 0.000 description 122
- 101000973232 Homo sapiens E3 ubiquitin-protein ligase NEURL1 Proteins 0.000 description 98
- 230000014509 gene expression Effects 0.000 description 94
- 108020004999 messenger RNA Proteins 0.000 description 80
- 101150024252 Neu1 gene Proteins 0.000 description 62
- 210000004940 nucleus Anatomy 0.000 description 56
- 210000004556 brain Anatomy 0.000 description 51
- 230000006870 function Effects 0.000 description 49
- 235000001014 amino acid Nutrition 0.000 description 42
- 241000282414 Homo sapiens Species 0.000 description 41
- 210000001519 tissue Anatomy 0.000 description 35
- 230000000694 effects Effects 0.000 description 34
- 241000700159 Rattus Species 0.000 description 33
- 210000001320 hippocampus Anatomy 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 30
- 210000002569 neuron Anatomy 0.000 description 29
- 239000002299 complementary DNA Substances 0.000 description 27
- 239000012634 fragment Substances 0.000 description 26
- 238000009396 hybridization Methods 0.000 description 26
- 230000001537 neural effect Effects 0.000 description 26
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 25
- 210000003710 cerebral cortex Anatomy 0.000 description 24
- 108020001507 fusion proteins Proteins 0.000 description 21
- 102000037865 fusion proteins Human genes 0.000 description 21
- 230000003993 interaction Effects 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 description 19
- 210000003205 muscle Anatomy 0.000 description 19
- 230000011664 signaling Effects 0.000 description 19
- 101000973235 Mus musculus E3 ubiquitin-protein ligase NEURL1 Proteins 0.000 description 18
- 238000002372 labelling Methods 0.000 description 18
- 210000001638 cerebellum Anatomy 0.000 description 17
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 210000000653 nervous system Anatomy 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 15
- 108010029485 Protein Isoforms Proteins 0.000 description 15
- 102000001708 Protein Isoforms Human genes 0.000 description 15
- 210000001947 dentate gyrus Anatomy 0.000 description 15
- 108010070047 Notch Receptors Proteins 0.000 description 14
- 102000005650 Notch Receptors Human genes 0.000 description 14
- 108091006107 transcriptional repressors Proteins 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 13
- 230000001272 neurogenic effect Effects 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 230000004807 localization Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 102100036254 E3 SUMO-protein ligase PIAS2 Human genes 0.000 description 11
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 11
- 239000013613 expression plasmid Substances 0.000 description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 10
- 239000000074 antisense oligonucleotide Substances 0.000 description 10
- 238000012230 antisense oligonucleotides Methods 0.000 description 10
- 108700020302 erbB-2 Genes Proteins 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 210000001103 thalamus Anatomy 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 230000004568 DNA-binding Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102100025169 Max-binding protein MNT Human genes 0.000 description 9
- 102000006382 Ribonucleases Human genes 0.000 description 9
- 108010083644 Ribonucleases Proteins 0.000 description 9
- 102000040945 Transcription factor Human genes 0.000 description 9
- 108091023040 Transcription factor Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 210000001259 mesencephalon Anatomy 0.000 description 9
- 210000001577 neostriatum Anatomy 0.000 description 9
- 210000002027 skeletal muscle Anatomy 0.000 description 9
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 8
- 102100029095 Exportin-1 Human genes 0.000 description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 101150084651 Neu2 gene Proteins 0.000 description 8
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000007547 defect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108700002148 exportin 1 Proteins 0.000 description 8
- 210000001905 globus pallidus Anatomy 0.000 description 8
- 210000003016 hypothalamus Anatomy 0.000 description 8
- 238000007901 in situ hybridization Methods 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 230000030648 nucleus localization Effects 0.000 description 8
- 210000002975 pon Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001541 thymus gland Anatomy 0.000 description 8
- 108010001515 Galectin 4 Proteins 0.000 description 7
- 102100039556 Galectin-4 Human genes 0.000 description 7
- 101001074629 Homo sapiens E3 SUMO-protein ligase PIAS2 Proteins 0.000 description 7
- YACHGFWEQXFSBS-UHFFFAOYSA-N Leptomycin B Natural products OC(=O)C=C(C)CC(C)C(O)C(C)C(=O)C(C)C=C(C)C=CCC(C)C=C(CC)C=CC1OC(=O)C=CC1C YACHGFWEQXFSBS-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- YACHGFWEQXFSBS-XYERBDPFSA-N leptomycin B Chemical compound OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)/C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-XYERBDPFSA-N 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 230000007542 postnatal development Effects 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 6
- 108700002232 Immediate-Early Genes Proteins 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 6
- 101100079850 Rattus norvegicus Neu1 gene Proteins 0.000 description 6
- 101710185494 Zinc finger protein Proteins 0.000 description 6
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
- 230000009456 molecular mechanism Effects 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 230000004766 neurogenesis Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 210000003594 spinal ganglia Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 210000001550 testis Anatomy 0.000 description 6
- 210000000575 ventromedial hypothalamic nucleus Anatomy 0.000 description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 102100035989 E3 SUMO-protein ligase PIAS1 Human genes 0.000 description 5
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 5
- 101100079847 Mus musculus Neu1 gene Proteins 0.000 description 5
- 101150029672 Neu3 gene Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 210000004727 amygdala Anatomy 0.000 description 5
- 210000001787 dendrite Anatomy 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002052 molecular layer Substances 0.000 description 5
- 230000030147 nuclear export Effects 0.000 description 5
- 230000012223 nuclear import Effects 0.000 description 5
- 230000006849 nucleocytoplasmic transport Effects 0.000 description 5
- 210000000956 olfactory bulb Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 230000000542 thalamic effect Effects 0.000 description 5
- 210000004001 thalamic nuclei Anatomy 0.000 description 5
- 238000001086 yeast two-hybrid system Methods 0.000 description 5
- 102100032187 Androgen receptor Human genes 0.000 description 4
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 description 4
- 102100034189 E3 ubiquitin-protein ligase RNF14 Human genes 0.000 description 4
- 101000712013 Homo sapiens E3 ubiquitin-protein ligase RNF14 Proteins 0.000 description 4
- 101000801209 Homo sapiens Transducin-like enhancer protein 4 Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 108010066154 Nuclear Export Signals Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 101150094313 XPO1 gene Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 108010080146 androgen receptors Proteins 0.000 description 4
- 210000004227 basal ganglia Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004565 granule cell Anatomy 0.000 description 4
- 210000001753 habenula Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000004960 subcellular localization Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000037426 transcriptional repression Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 101000979249 Homo sapiens Neuromodulin Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 102100023206 Neuromodulin Human genes 0.000 description 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 102100033763 Transducin-like enhancer protein 4 Human genes 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000030570 cellular localization Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000002233 diagonal band of broca Anatomy 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000002555 ionophore Substances 0.000 description 3
- 230000000236 ionophoric effect Effects 0.000 description 3
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 3
- 229950006874 kainic acid Drugs 0.000 description 3
- 230000023886 lateral inhibition Effects 0.000 description 3
- 210000000627 locus coeruleus Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004879 molecular function Effects 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 210000003757 neuroblast Anatomy 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 230000004031 neuronal differentiation Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 102000045222 parkin Human genes 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 210000002637 putamen Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000022379 skeletal muscle tissue development Effects 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- MLYCFWZIAJAIGW-UHFFFAOYSA-N 1-(2,5-dimethoxy-4-methylphenyl)butan-2-amine Chemical compound CCC(N)CC1=CC(OC)=C(C)C=C1OC MLYCFWZIAJAIGW-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241001064577 Ariadne <plant> Species 0.000 description 2
- 108700020463 BRCA1 Proteins 0.000 description 2
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 108010035533 Drosophila Proteins Proteins 0.000 description 2
- 101710191251 E3 SUMO-protein ligase PIAS2 Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108700005087 Homeobox Genes Proteins 0.000 description 2
- 101000765033 Homo sapiens Class E basic helix-loop-helix protein 41 Proteins 0.000 description 2
- 101001001478 Homo sapiens Importin subunit alpha-3 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101001123851 Homo sapiens Sialidase-2 Proteins 0.000 description 2
- 101001123847 Homo sapiens Sialidase-3 Proteins 0.000 description 2
- 101000601384 Homo sapiens Sialidase-4 Proteins 0.000 description 2
- 102100036188 Importin subunit alpha-3 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101150118570 Msx2 gene Proteins 0.000 description 2
- 101100079857 Mus musculus Neu3 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241001282736 Oriens Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000042637 PIAS family Human genes 0.000 description 2
- 108091053406 PIAS family Proteins 0.000 description 2
- 101150086423 PIAS2 gene Proteins 0.000 description 2
- 101150059738 Pcgf2 gene Proteins 0.000 description 2
- 102100040919 Polycomb group RING finger protein 2 Human genes 0.000 description 2
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 2
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 101100079854 Rattus norvegicus Neu2 gene Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010077099 alpha Karyopherins Proteins 0.000 description 2
- 102000009899 alpha Karyopherins Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000008303 genetic mechanism Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 102000051957 human ERBB2 Human genes 0.000 description 2
- 102000054572 human NEU2 Human genes 0.000 description 2
- 102000047925 human NEU4 Human genes 0.000 description 2
- 102000047740 human Neu3 Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 108091069124 importin alpha family Proteins 0.000 description 2
- 102000039981 importin alpha family Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000004492 nuclear pore Anatomy 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000002509 periaqueductal gray Anatomy 0.000 description 2
- 210000004560 pineal gland Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 210000000449 purkinje cell Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000003863 superior colliculi Anatomy 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102100026190 Class E basic helix-loop-helix protein 41 Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108700019125 Drosophila Em7-HLH Proteins 0.000 description 1
- 101000894430 Drosophila melanogaster C-terminal-binding protein Proteins 0.000 description 1
- 108700032209 Drosophila neur Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 101150096607 Fosl2 gene Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100032863 General transcription factor IIH subunit 3 Human genes 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 229940117892 Glutamate receptor agonist Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 description 1
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 1
- 108091069688 Homer family Proteins 0.000 description 1
- 102000040058 Homer family Human genes 0.000 description 1
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 1
- 101001015963 Homo sapiens E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 101000666405 Homo sapiens General transcription factor IIH subunit 1 Proteins 0.000 description 1
- 101000655398 Homo sapiens General transcription factor IIH subunit 2 Proteins 0.000 description 1
- 101000655391 Homo sapiens General transcription factor IIH subunit 3 Proteins 0.000 description 1
- 101000655406 Homo sapiens General transcription factor IIH subunit 4 Proteins 0.000 description 1
- 101000655402 Homo sapiens General transcription factor IIH subunit 5 Proteins 0.000 description 1
- 101100079846 Homo sapiens NEU1 gene Proteins 0.000 description 1
- 101001123859 Homo sapiens Sialidase-1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000795753 Homo sapiens mRNA decay activator protein ZFP36 Proteins 0.000 description 1
- 101000802101 Homo sapiens mRNA decay activator protein ZFP36L2 Proteins 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 101150026829 JUNB gene Proteins 0.000 description 1
- 101150021395 JUND gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 101100186921 Legionella pneumophila subsp. pneumophila (strain Philadelphia 1 / ATCC 33152 / DSM 7513) neuB gene Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100501690 Mus musculus Erbb2 gene Proteins 0.000 description 1
- 101100024551 Mus musculus Msx3 gene Proteins 0.000 description 1
- 102100038380 Myogenic factor 5 Human genes 0.000 description 1
- 101710099061 Myogenic factor 5 Proteins 0.000 description 1
- 102100038379 Myogenic factor 6 Human genes 0.000 description 1
- 102100032970 Myogenin Human genes 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 241001481166 Nautilus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102100023057 Neurofilament light polypeptide Human genes 0.000 description 1
- 102000001759 Notch1 Receptor Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010038241 Protein Inhibitors of Activated STAT Proteins 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 101100501691 Rattus norvegicus Erbb2 gene Proteins 0.000 description 1
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108010072819 STAT Transcription Factors Proteins 0.000 description 1
- 102000007078 STAT Transcription Factors Human genes 0.000 description 1
- ZVHPYMRQVUPXNX-UHFFFAOYSA-N Saurin Natural products OCC1C2CC(O)C(=C)C3C(C2OC1=O)C(=C)CC3=O ZVHPYMRQVUPXNX-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100029462 Sodium-dependent lysophosphatidylcholine symporter 1 Human genes 0.000 description 1
- 101710185583 Sodium-dependent lysophosphatidylcholine symporter 1 Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 1
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000001681 anterior hypothalamic nucleus Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003198 cerebellar cortex Anatomy 0.000 description 1
- 210000003591 cerebellar nuclei Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 210000002108 dorsomedial hypothalamic nucleus Anatomy 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003823 glutamate receptor agonist Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000002990 hypoglossal effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000003552 inferior colliculi Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 102100031622 mRNA decay activator protein ZFP36 Human genes 0.000 description 1
- 102100034703 mRNA decay activator protein ZFP36L2 Human genes 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000000218 midline thalamic nuclei Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000012514 monoclonal antibody product Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 108010084677 myogenic factor 6 Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 108010090677 neurofilament protein L Proteins 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000003565 oculomotor Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 208000022587 qualitative or quantitative defects of dystrophin Diseases 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 108091008761 retinoic acid receptors β Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical class OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 210000001679 solitary nucleus Anatomy 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000004092 somatosensory cortex Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002538 spinal trigeminal nucleus Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000004515 ventral tegmental area Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 210000004440 vestibular nuclei Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the described invention relates to the family of mammalian Neuralized (neu) genes, proteins encoded by those genes (Neu), expression patterns of the gene family, their function as a transcriptional regulator, and the proteins with which the Neu family of proteins interacts. Additionally, therapeutic and diagnostic uses for the Neu family of proteins and agents that bind thereto are also provided.
- Neu mammalian Neuralized
- the process of lateral inhibition prevents neighboring cells from developing into the same type of differentiated cells in flies and in vertebrates. Tanabe & Jessell, Science, 274:1115-23 (1996).
- Drosophila a group of mutations has been described that shows severe defects in the process of lateral inhibition in the developing nervous system. These neurogenic mutations result in hyperplasia of the neural tissue at the expense of epidermal structures. Campos-Ortega & Jan, Annu Rev Neurosci, 14:399-420 (1991).
- the temporal and spatial expression patterns of the neu are compatible with its function as a neurogenic gene in Drosophila .
- the Neu protein is expressed throughout the ectoderm at the time when cell fate is determined and its expression proceeds in neuroblasts. Boulianne, et al., EMBO J, 10:2975-2983 (1991). neu expression has been detected in actively proliferating neuroblasts in several regions of the CNS and PNS. Expression of neu in imaginal disc suggests that it is also involved in later stages of development.
- the neu gene encodes a RING finger (C3HC4) type zinc finger protein.
- the molecular function of the Drosophila Neu protein is unknown. Interestingly, it was discovered that EST data bases contain a homologue of Neu suggesting that a family of Neu-like proteins is present in Drosophila.
- Drosophila neural precursors are first specified by proneural genes including basic helix-loop-helix (bHLH) transcription factors of atonal and achaete-scute complex.
- bHLH basic helix-loop-helix
- Simpson Neuron, 15:739-742 (1995).
- the process of lateral inhibition which further restricts the developmental potential of neuroectodermal cells is regulated by neurogenic genes such as Notch, mastermind, big brain, Delta, Enhancer of split, and neuralized.
- the disclosure relates to isolated polynucleotides and purified polypeptides of the Neu family of proteins, which have been shown to demonstrate transcriptional regulatory activity.
- the purified polynucleotide can encode a Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed.
- a purified Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed.
- Antibodies capable of specifically binding to the disclosed Neu polypeptides are disclosed.
- FIG. 1 shows the primary structure of neu1 protein isoforms in mouse and rat.
- FIG. 2 is an analysis of neu1 mRNA expression by RNase protection assay in mouse and rat.
- FIG. 3 is an in situ hybridization analysis of neu1 mRNA expression in the developing and adult mouse brain.
- FIG. 4 is an in situ hybridization analysis of neu1 mRNA expression in adult rat brain.
- FIG. 5 shows expression of neu1 mRNA in an adult rat nervous system.
- FIG. 6 shows cellular localization of neu1 mRNA in an adult rat nervous system.
- FIG. 7 shows the combined analyses of in situ hybridization of neu1 mRNA and immunohistochemistry of the neuronal marker neuN.
- FIG. 8 shows neu1 mRNA expression in the hippocampus of adult rat brain after kainic acid treatment.
- FIG. 9 shows transcriptional analysis from various promoters in transient expression assays.
- FIG. 10 shows that neuralized homology repeat domains of neu1 mediate the transcriptional repression when fused to the DNA binding domain of Gal4.
- FIG. 11 shows the subcellular localization of neu-FLAG and neu-EGFP fusion proteins in Neuro2A cells, using FLAG immunofluorescence using anti-FLAG antibody (A, E, F, G) and direct fluorescence of EGFP fusion proteins (B, C, D, H).
- FIG. 12 shows alignment of neuralized homology repeat domains of human Neu1, Neu2, and Neu3 proteins.
- FIG. 13 shows the analysis of neu2 mRNA expression by RNase protection assay in mouse and rat.
- FIG. 14 shows the analysis of neu3 mRNA expression by RNase protection in mouse.
- FIG. 15 is an analysis of the expression of rat Neu1 interactors by RNase protection assay.
- the invention described herein relates to the identification of members of the Neuralized (neu) family of genes and their respective proteins, and aspects of their structure and function as transcriptional regulators.
- the invention relates to the characteristics of mammalian neu gene family's conserved structural motifs, related function as transcriptional regulators, and functional features of the family relating to expression patterns and potential interactions with interaction-partners, providing tools with which to explore the Neu-related regulatory cascades that operate in neurons and other cell types.
- the invention described herein relates to the neuralized (Neu) family of transcriptional regulators that contain a C-terminal C3HC4 RING zinc finger and at least one neuralized homology repeat domain.
- the term “neuralized” (or “Neu”) includes all members of the Neu family such as Neu1, Neu2, Neu3, Neu4 coding sequences and proteins. These proteins belong to a family of proteins that share C-terminal C3HC4 RING zinc finger and at least one neuralized homology repeat domain. Neuralized homology repeat domains represent a novel class of transcription repression domains that regulate transcription of a large number of genes.
- the C3HC4 RING-zinc finger motif is a cystine-rich amino acid sequence motif found in the sequence of the human RING gene. Freemont, et al., Biochem J, 278:1-23 (1991); Freemont, Ann NY Acad Sci, 684:174-192 (1993).
- the motif can be described as C—X 2 —C—X (9-27) —C—X (1-3) —H—X 2 —C—X 2 —C—X (4-48) —C—X 2 —C, where C is a cysteine, H is a histamine, and X can be any amino acid.
- This family includes genes that are involved in the regulation of development, differentiation, apoptosis, oncogenesis, and membrane trafficking.
- RING-zinc finger proteins have proposed roles in gene regulation. Although the precise function of the RING-zinc finger domain is unknown, indirect data demonstrates that the RING-zinc finger domain could function as a DNA-binding or protein-protein interaction domain. These two functions are related.
- transcriptional repressors which act as dimers have been characterized. Their structures comprise both dimerization and DNA-binding surfaces.
- transcriptional regulators that contain RING-zinc finger domains are BRCA1 (Miki et al., Science, 266(5182):66-71 (1994)) and MEL18 (Kanno et al., EMBO J. 15;14(22):5672-8 (1995)), a polycomb group-related transcriptional regulator.
- Mammalian Neu1 acts as a powerful transcriptional repressor in transient expression assays and silences both, TATA-containing and TATA-less promoters, including the promoters of NGF, BDNF, NF-L, and GAP-43. NHRs function as transcription repression domains, suggesting that NHR-containing proteins represent a novel class of transcriptional repressors. It is likely that mammalian Neu1 mediates transcriptional repression through protein-protein interactions.
- mammalian Neu1 could function through interaction with co-repressors such as dCtBP or mammalian homologues of Groucho, and general repressor complexes, such as NC2, Mot1, or Not to interfere with the function of Pol II complex. Maldonado et al., Cell, 99:455-458 (1999) and Mannervik et al., Science, 284:606-609 (1999). Alternatively, repression could be achieved through chromatin remodeling by recruiting the histone deacetylase complexes (HDACs).
- HDACs histone deacetylase complexes
- a putative nuclear localization signal has been identified in the N-terminus of d-Neu, however, the NLS sequence identified in d-Neu, is not conserved in mouse, rat and human Neu proteins. Boulianne et al., EMBO J 10:2975-2983 (1991) and Price et al., EMBO J, 12:2411-2418 (1993).
- the weak NLS sequences (HKAVKR (SEQ ID NO: 43), RLKITKK (SEQ ID NO: 44)), that were identified in mammalian Neu1 proteins, have been suggested to regulate nuclear import of a fraction of the synthesized protein. Boulikas, J Cell Biochem, 60:61-82 (1996).
- m-Neu1 resides both in the cytoplasm and in the nucleus, revealing that it is the subject of regulated nuclear import.
- importin- ⁇ family members are involved in the formation of the NLS receptor complexes that govern the protein transport to the nucleus. Ullman et al., Cell, 90:967-970 (1997); and Izaurralde and Adam, RNA, 4:351-364 (1998).
- importin- ⁇ 3 was identified here as one of the m-Neu interacting proteins by yeast two-hybrid screening.
- results discussed herein demonstrate that the CRM1/exportin1-related export pathway controls the nucleocytoplasmic shuttling of Neu1, since the nuclear export of a tagged-m-Neu1 fusion protein is blocked by LMB.
- LMB is a microbial metabolite that inactivates the nuclear export by interfering with the binding of CRM1/exportin1 to the nuclear export signals.
- Transcriptional activity of Neu is controlled by calcium (Ca 2+ ) signaling that regulates Neu translocation into the nucleus where Neu acts as a transcriptional repressor. It has been long known that intracellular calcium controls a variety of brain- and muscle cell functions. Since Ca 2+ levels regulate nucleocytoplasmic shuttling of transcription factors (Crabtree, Cell, 96:611-614 (1999)), Neu proteins could function as mediators of calcium signaling to the nucleus to regulate gene expression.
- Drosophila neuralized (d-neu) and h-neu1 genes encode homologous ( ⁇ 40%) proteins with a C-terminal C3HC4 RING zinc finger domain (RZD) and one or two neuralized homology repeat (NHR) domains.
- RZD RING zinc finger domain
- NHR neuralized homology repeat
- neu1 defines a new gene and protein family consisting of at least two Drosophila and four mammalian genes.neu2, second member of mammalian neu family of genes, is expressed at high levels in the embryonic brain, whereas the expression levels decrease during postnatal development.
- Suppression of gene expression plays an important role in the maintenance and stability of a mature nervous system. It is essential to suppress neurite growth and extensive formation of new axons and dendrites in the adult functional nervous system and to maintain neurons in their differentiated state. Transcriptional repressors are involved and play a crucial role in the silencing of the neurite growth program.
- Mammalian neu1 shows most prominent expression in the postnatal central nervous system, revealing its function in postnatal development. neu1 mRNA expression levels increase significantly during the early postnatal development when active synaptogenesis takes place, to reach the peak levels in the adult animal. In the adult mammalian CNS, the highest expression levels of neu1 assign to the neurons of hippocampus, cerebral cortex, striatum, and amygdala. Whereas several brain regions such as thalamus/hypothalamus, midbrain, medulla, and also the spinal cord exhibit low expression. This indicates to the independent regulation of neu1 expression in various brain regions by specific signaling mechanisms as well as to the requirement of Neu function for different cell-cell signaling systems.
- neu1 mRNA expression studies in adult rat brain revealed that in several brain regions, particularly in the granular cells of dentate gyrus of hippocampus, neu1 mRNA is localized in the dendrites, suggesting that synthesis of Neu1 protein also occurs in dendrites.
- a specific temporal order of events at the cellular and molecular level occurs in response to injury to the brain.
- Injury-compromised neurons degenerate while surviving neurons undergo neuritogenesis and synaptogenesis to establish neuronal connectivity destroyed in the injury.
- kainate-induced change in neuronal activity a neurotoxic, excitotoxic or ischemic insult
- down-regulation of neu1 mRNA expression leads to reduced levels of Neu1 protein that is essential for derepression of the transcription of its target genes related to repair and regeneration, such as growth factors and synaptic proteins.
- a member of Homer family of proteins, Homer2a is referred to as an interactor of human Neu1 (GenBank Acc. No. AF081530).
- Homer proteins are enriched in excitatory synapses, bind group I metabotropic glutamate receptors (mGluR), and NMDA receptor interacting Shank proteins and thus can link NMDA and group I mGluR signaling pathways (reviewed in Xiao et al., Curr Opin Neurobiol, 10:370-74 (2000)).
- Neu1 participates in the regulation of glutamate receptor signalling in the adult brain.
- Glutamate receptor signaling has been implicated in several forms of activity-dependent synaptic plasticity, neurodegenerative diseases, cortical development and addiction. Consequently, if Neu is involved in glutamate receptor signaling, then the change in Neu structure, expression or function could lead to various developmental disorders and mental diseases.
- neu1 mRNA expression is regulated by physiological neuronal synaptic activity leading to reduced levels of Neu1 protein and derepression of the transcription of its target genes in the processes involving memory and learning.
- This function of the Neu family transcription factors makes them a good target for a variety of drugs that control different processes in the brain, during development and in disease. Manipulating this function of Neu can be used to control a variety of diseases including depression, pain, anxiety, and neurodegenerative diseases.
- this invention relates to the role of the Neu family of factors in the development of tumors, since the human neu1 gene has been mapped to chromosome 10 within a region which is frequently deleted in gliomas. neu1 is expressed at varying levels in different neural and neuroendocrine tumors, including neuroblastomas, carcinoids, non-small cell lung cancers, and gliomas, suggesting that expression of Neu family of proteins is applicable as tumor-specific markers in clinical tumor diagnostics. Since over-expression of Neu1 blocks DNA synthesis in neuroblastoma and glioma cells, Neu family of proteins may function also as tumor suppressor genes.
- neu1 and neu2 show that expression of neu1 and neu2 is found to be high in at late embryonic and adult stages of development, also in developing heart and testes.
- neu3 was found to be widely expressed, with highest levels in immune tissues spleen and thymus and in lung.
- Expression of neu4 was detected only in muscle and heart. Since Neu proteins are expressed at various levels in many different body systems, the role of Neu family of proteins in several developmental pathways is apparent. Studies of neu mut flies have reported the overproduction of nautilus (nau) expressing cells in embryonic and muscle defects in adult stages of development. Corbin et al., Cell, 67:311-323 (1991); Hartenstein et al., Development, 116:1203-1220 (1992).
- nau is a myogenic bHLH factor that plays a role in the differentiation of muscle progenitors in Drosophila .
- Notch signaling has been shown to inhibit MyoD expression and block myogenesis in mouse. Kuroda et al., J Biol Chem, 274:7238-7244 (1999). It is possible that during mammalian myogenesis Neu refines Notch signaling by regulating expression of nau mammalian homologues (MyoD, myf5, myogenin and MRF4).
- Neu family of transcription factors Another function of the Neu family of transcription factors is mediation of Ca 2+ signaling in muscle and other tissues. This function of the Neu family transcription factors makes them a good target for a variety of drugs that control different processes in the muscle, and in those tissues where Neu is expressed. Manipulating Neu expression and function can be used to control a variety of diseases including cancer, and muscle-degenerative diseases, dystrophinopathies, Brody's disease, and malignant hyperthermia (the last three are caused by the functional alterations of Ca(2+) signaling).
- the nucleocytoplasmic transport of functional molecules is mediated bidirectionally through the nuclear pore complex (NPC), which spans the double membranes of the nuclear envelope. It has recently been shown that signaling between the nucleus and the cytoplasm plays a key role in coordinating the cellular processes such as the cell cycle and cell differentiation (Yoneda, Cell Struct Funct 25:205-206. 2000).
- the weak NLS sequences (HKAVKR (SEQ ID NO: 43), RLKITKK (SEQ ID NO: 44)
- Importin- ⁇ family members are involved in the formation of the NLS receptor complexes that govern the protein transport to the nucleus.
- Miz1 is a sequence specific DNA binding protein that functions as a positive-acting transcription factor and interacts directly with homeobox transcription factor Msx2.
- Msx1 and Msx2 members of the Msx family of homeobox genes, were found to be important in inductive tissue interactions. Whereas Msx3 was expressed exclusively in the developing nervous system. Wang, et al., Mech Dev, 58(1-2):203-15 (1996).
- PIAS1 is identical to Gu/RNA helicase II (Gu/RH-II) binding protein GBP. Valdez et al., Biochem Biophys Res Commun, 234(2):335-40 (1997).
- the GBP regulates proteolytic cleavage of Gu/RH-II which could alter its functions or enzymatic activities or lead to its destruction.
- ZNF127 zinc finger family of proteins.
- the ZNF127 gene is localized in Angelman/Prader-Willi region. Disruption of this gene causes a genetic defect related to mental retardation. ZNF127, as well as other genes in this region, were subjected to genomic imprinting (Mowery-Rushton et al., DNA methylation patterns in human tissues of uniparental origin using a zinc-finger gene (ZNF127) from the Angelman/Prader-Willi region Am J Med Genet, 61(2):140-6 (1996)).
- ZNF127 The role of ZNF127 in the development of Angelman/Prader-Willi syndrome, as well as its molecular function, is unknown.
- the ZNF127 family proteins contain the zinc finger motif, Cx(8)Cx(5)Cx(3)-H, which is characteristic for viral and early immediate genes such as TIS11, ERF-2 (Tabara et al., 1999 pos-1 encodes a cytoplasmic zinc-finger protein essential for germline specification in C. elegans Development, 126(1):1-11); and also to RNA binding proteins (Carballo et al. Science, 281:1001-1005 (1998)).
- the NeuI-3 protein is another interactor with Neu1 and was found to be similar to the recently described human gene parkin (Kitada, et al., Nature 392(6676):605-8 (1998). Mutations in the parkin gene have been shown to result in autosomal recessive juvenile parkinsonism. The molecular function of the parkin encoded protein is unknown. Phylogenetic analysis reveals that ari and parkin are distant members of a common progeny.
- NeuI-4 another Neu interactor, is identical to ARA54, an androgen receptor coregulator (Kang et al., J. Biol. Chem. 274, 8570-8576; 1999). Furthermore, the RING-zinc finger domain of NeuI-4 has high similarity to Drosophila protein ariadne (ari) that could be involved in axonal path-finding. Aguilera, et al., Genetics 155(3):1231-44 (1996). Two mammalian homologues of ari have been identified, however, no information is available about molecular mechanisms of the functioning of the ari family of proteins.
- Neu has the potential to interfere with inductive tissue interactions (NeuI-1/Miz), cytokine signalling (NeuI-1/PIAS), RNA processing (NeuI-1/GBP), early immediate responses (NeuI-2/ZNF127), death of specific cell populations (NeuI-3/parkin), and nuclear hormone receptor signaling and axonal path-finding (NeuI-4/ariadne).
- the described invention seeks to utilize this knowledge to manipulate the various developmental pathways in which Neu functions.
- representative members of the Neu family of proteins have been isolated and purified.
- Polynucleotide molecules encoding the proteins of the Neu family were then isolated and their sequences are provided below.
- Representative polynucleotide molecules encoding members of the Neu family include sequences comprising SEQ. ID. NOs.: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33.
- Polynucleotide molecules encoding Neu family members include those sequences resulting in minor genetic polymorphisms, differences between species, and those that contain amino acid substitutions, additions, and/or deletions.
- Such changes can also be directed towards endogenous neu sequences using, for example, gene therapy methods to alter the gene product.
- the disclosed sequences can be used to identify and isolate neu polynucleotide encoding molecules from suitable vertebrate host cells.
- a method of identifying neu polynucleotide molecules is provided.
- the nucleotide sequences encoding the neuralized homology repeat domain can be used to identify polynucleotide molecules encoding other proteins of the Neu family.
- Complementary DNA molecules encoding Neu family members can be obtained by constructing a cDNA library from mRNA of, for example, brain or muscle tissues that are at different developmental stages. DNA molecules encoding Neu family members can be isolated from such a library using the disclosed sequences in standard hybridization techniques or by amplification of sequences using polymerase chain reaction (PCR) amplification.
- PCR polymerase chain reaction
- genomic DNA encoding Neu can be obtained using probes designed from the sequences disclosed herein.
- Suitable probes for use in identifying Neu family sequences can be obtained from Neu-specific sequences that are highly conserved regions between mammalian coding sequences.
- Primers, for example, from the neuralized homology motif domains 1 and 2 are suitable for use in designing PCR primers.
- oligonucleotides containing specific DNA sequences from a neu family coding region can be used to identify related human neu genomic and cDNA clones.
- upstream regulatory regions of the neu family of genes can be obtained using similar methods.
- neu family polynucleotide molecules can be isolated using standard hybridization techniques with probes of at least about 7 nucleotides in length and up to and including the full coding sequence. Other members of the neu family can be identified using degenerate oligonucleotides capable of hybridization based on the sequences disclosed herein for use PCR amplification or by hybridization at moderate or greater stringency.
- the term, “capable of hybridization” as used herein means that the subject nucleic acid molecules (whether DNA or RNA) anneal to an oligonucleotide of 15 or more contiguous nucleotides of SEQ. ID. NOs.: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33.
- hybridization stringency can be altered by: adjusting the temperature of hybridization; adjusting the percentage of helix-destabilizing agents, such as formamide, in the hybridization mix; and adjusting the temperature and salt concentration of the wash solutions. In general, the stringency of hybridization is adjusted during the post-hybridization washes by varying the salt concentration and/or the temperature, resulting in progressively higher stringency conditions.
- An example of progressively higher stringency conditions is as follows: 2 ⁇ SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 ⁇ SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 ⁇ SSC/0.1% SDS at about 42° C. (moderate stringency conditions); and 0.1 ⁇ SSC at about 68° C. (high stringency conditions). Washing can be carried out using only one of these conditions, e.g., high stringency conditions, or each of the conditions can be used, e.g., for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically. In general, conditions of high stringency are used for the hybridization of the probe of interest.
- polynucleotides having substantially the same nucleotide sequence set forth in SEQ. ID. NOs.: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33 or functional fragments thereof, or nucleotide sequences that are substantially identical to SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33, can represent members of the Neu family of proteins.
- substantially the same” or “substantially identical” is meant a nucleic acid or polypeptide exhibiting at least 80%, 85%, 90%, 95% or 100% homology to a reference nucleic acid.
- the length of comparison sequences will generally be at least 10 to 500 nucleotides in length. More specifically, the length of comparison will be at least 50 nucleotides, at least 60 nucleotides, at least 75 nucleotides, and at least 110 nucleotides in length.
- One embodiment of the invention provides isolated and purified polynucleotide molecules encoding Neu proteins, wherein the polynucleotide molecules that are capable of hybridizing under moderate to stringent conditions to an oligonucleotide of 15 or more contiguous nucleotides of SEQ. ID. NOs.: 1, 3, 5, 7,9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33, including complementary strands thereto.
- DNA sequences of the invention can be obtained by several methods.
- the DNA can be isolated using hybridization or computer-based techniques which are well known in the art. Such techniques include, but are not limited to: 1) hybridization of genomic or cDNA libraries with probes to detect homologous nucleotide sequences; 2) antibody screening of expression libraries to detect cloned DNA fragments with shared structural features; 3) polymerase chain reaction (PCR) on genomic DNA or cDNA using primers capable of annealing to the DNA sequence of interest; 4) computer searches of sequence databases for similar sequences; and 5) differential screening of a subtracted DNA library.
- PCR polymerase chain reaction
- Oligonucleotide probes which correspond to a part of the neu family of sequences provided herein and encoding a Neu protein family member, can be synthesized chemically. This requires that short, oligo-peptide stretches of the amino acid sequence be known.
- the DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate. This includes a heterogeneous mixture of denatured double-stranded DNA.
- hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA.
- Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present.
- stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete complement.
- a subtractive library is useful for elimination of non-specific cDNA clones.
- plasmid- or phage-carrying cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of gene expression.
- phage-carrying cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of gene expression.
- the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA can be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single-stranded form (Jay, et al., Nucl. Acid Res., 11:2325, 1983).
- nucleotide sequences of the present invention have a myriad of applications.
- Representative uses of the nucleotide sequences of the invention include the construction of cDNA and oligonucleotide probes useful in Northern, Southern, and dot-blot assays for identifying and quantifying the level of expression of Neu family proteins in a cell. Lack of expression of a Neu protein in tumors, diseased cells or tissues can indicate that measuring the level of Neu expression can provide prognostic markers for assessing the growth rate and invasiveness of a tumor.
- Neu protein family can prove highly useful in prenatal screening of mothers and/or for in utero testing of fetuses.
- early diagnosis of degenerative and neurological diseases can be based on the analyses of changes in Neu expression and mutations in the neu genes.
- nucleotide sequences can be employed for the construction of recombinant cell lines, ova, and transgenic embryos and animals including dominant-negative and “knock-out” recombinant cell lines in which the regulatory activity of Neu protein is down-regulated or eliminated.
- Such cells can contain altered Neu coding sequences that result in the expression of a Neu protein that is not capable of enhancing, suppressing or activating transcription of the target gene.
- the subject cell lines and animals find use in screening for candidate therapeutic agents capable of either substituting for a function performed by Neu or correcting the cellular defect caused by a defective Neu.
- the Neu family of proteins presents an attractive set of diagnostic and therapeutic targets, considering the important regulatory role this family of proteins plays in the development function of adult organisms. This important role is reflected by the effects one or defects in a mutant Neu protein can inflict upon an organism. Moreover, with the advances in art of gene therapy progresses, these defects can be correctable in utero or in early post-natal life or alternatively through the use of compounds identified in screening assays using Neu proteins.
- neu polynucleotide molecules can be joined to reporter genes, such as beta-galactosidase, luciferase, or green fluorescent proteins (GFP) and inserted into the genome of a suitable host cell such as an embryonic or tissue specific stem cell by, for example, homologous recombination.
- reporter genes such as beta-galactosidase, luciferase, or green fluorescent proteins (GFP)
- GFP green fluorescent proteins
- Cells expressing neu can then be obtained by subjecting the differentiating cells to cell sorting, leading to the purification of a population of neu expressing cells.
- These cells can be useful for studying specific activity of isolated cell populations. Also, these cells can be used to study sensitivity to growth factors or chemotherapeutic agents.
- the technology can be useful in the construction of gene transfer vectors (e.g., retroviral vectors, and the like).
- the neu sequence is often inserted into the coding region of the vector under the control of a promoter.
- neu gene therapy can be used to correct neurological and movement diseases and cancer.
- gene transfer vectors can either be injected directly at the site of diseased cells, or the vectors can be used to construct transformed host cells that are then injected at the site of disease.
- a vector comprising a DNA molecule coding a Neu protein is provided.
- a DNA molecule coding a Neu protein is inserted into a suitable expression vector, which is in turn used to transfect or transform a suitable host cell.
- exemplary expression vectors for use in carrying out the present invention include a promoter capable of directing the transcription of a polynucleotide molecule of interest in a host cell.
- Representative expression vectors include both plasmid and/or viral vector sequences. Suitable vectors include retroviral vectors, vaccinia viral vectors, CMV viral vectors, BLUESCRIPT (Stratagene, San Diego, Calif.) vectors, baculovirus vectors, and the like.
- promoters capable of directing the transcription of a cloned gene or cDNA can be inducible or constitutive promoters and include viral and cellular promoters.
- viral vectors are employed for use in expressing Neu proteins in mammalian cells particularly if neu is used for gene therapy.
- selectable markers are generally introduced into the cells along with the cloned DNA molecules and include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. Selectable markers can also complement auxotrophies in the host cell. Other selectable markers provide detectable signals, such as beta-galactbsidase to identify cells containing the cloned DNA molecules.
- the selectable markers are amplifiable. Such amplifiable selectable markers can be used to amplify the number of sequences integrated into the host genome.
- Antisense neu nucleotide sequences can be used to block expression of mutant neu expression in a variety of cell types.
- Suitable antisense oligonucleotides are at least 11 nucleotides in length and can include untranslated (upstream or intron) and associated coding sequences.
- the optimal length of an anti sense oligonucleotide depends on the strength of the interaction between the antisense oligonucleotide and the complementary mRNA, the temperature and ionic environment in which translation takes place, the base sequence of the antisense oligonucleotide, and the presence of secondary and tertiary structure in the mRNA and/or in the antisense oligonucleotide.
- Suitable target sequences for antisense oligonucleotides include intron-exon junctions (to prevent proper splicing), regions in which DNA/RNA hybrids will prevent transport of mRNA from the nucleus to the cytoplasm, initiation factor binding sites, ribosome binding sites, and sites that interfere with ribosome progression.
- Antisense oligonucleotides can be prepared, for example, by the insertion of a DNA molecule containing the target DNA sequence into a suitable expression vector such that the DNA molecule is inserted downstream of a promoter in a reverse orientation as compared to the gene itself.
- the expression vector can then be transduced, transformed or transfected into a suitable cell resulting in the expression of antisense oligonucleotides.
- antisense oligonucleotides can be synthesized using standard manual or automated synthesis techniques. Synthesized oligonucleotides are introduced into suitable cells by a variety of means including electroporation, calcium phosphate precipitation, or microinjection.
- antisense oligonucleotide administration method will be evident to one skilled in the art.
- stabilizing agents include intercalating agents that are covalently attached to either or both ends of the oligonucleotide.
- the oligonucleotides are made resistant to nucleases by, for example, modifications to the phosphodiester backbone by the introduction of phosphotriesters, phosphonates, phosphorothioates, phosphoroselenoates, phosphoramidates, phosphorodithioates, or morpholino rings.
- the polynucleotide molecules of the present invention can be expressed in a variety of prokaryotic and eucaryotic organisms.
- the Neu family of proteins can be expressed in to, Saccharomyces cerevisiae, filamentous fungi, and bacteria, such as E. coli to produce Neu proteins.
- Neu proteins produced according to the present invention can be purified using a number of established methods such as affinity chromatography using anti-Neu antibodies coupled to a solid support. Fusion proteins of antigenic tag and Neu can be purified using antibodies to the tag. Optionally, additional purification is achieved using conventional purification means such as liquid chromatography, gradient centrifugation, and gel electrophoresis, among others. Methods of protein purification are known in the art and can be applied to the purification of recombinant Neu described herein.
- the identification of mammalian Neu genes is provided.
- the mammalian Neu genes have highly conserved sequences across the neuralized homology motif domains at the amino acid level (Neu1, Neu 2, Neu3, and Neu 4).
- the following Neu polypeptides or proteins have been identified: human neural Neu1 protein of SEQ. ID. NO.:2, human muscle Neu1 protein SEQ. ID. NO.:4; human Neu1 alternatively spliced form (h-neu1 ⁇ NHR1) of SEQ. ID. NO.: 6; mouse neural Neu1 protein of SEQ. ID. NO.: 8; mouse muscle Neu1 protein SEQ. ID. NO.: 10; mouse Neu1 alternatively spliced form (m-neu1 ⁇ NHR2A) of SEQ. ID.
- the described invention encompasses Neu variants that, for example, are modified in a manner that results in Neu proteins capable of translocating into the nucleus but unable to repress transcription. Fragments of Neu proteins that are capable of transcriptional repression but are incapable of translocating into the nucleus are also encompassed by the present description. Proteins retrieved from naturally occurring materials and closely related, functionally similar proteins retrieved by antisera specific to Neu, and recombinantly expressed proteins encoded by genetic materials (DNA, RNA, cDNA) retrieved on the basis of their similarity to the unique regions in the neu family of genes, are also encompassed by the present description.
- polynucleotide molecules encoding Neu encompass those molecules that encode Neu proteins or peptides that share identity with the sequences shown in SEQ. ID. NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34. Such molecules preferably share greater than 30% identity at the amino acid level with the disclosed sequences in Neu. In preferred embodiments, the polynucleotide molecules can share greater identity at the amino acid level across highly conserved regions such as the neuralized homology repeat domains and the RING-zinc finger domains.
- amino acid sequences substantially the same as the sequences set forth in SEQ. ID. NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34 are encompassed by the described invention.
- a preferred embodiment includes polypeptides having substantially the same sequence of amino acids as the amino acid sequence set forth in SEQ ID NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34, or functional fragments thereof, or amino acid sequences that are substantially identical to SEQ ID NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34.
- polypeptide exhibiting at least 80%, preferably 85%, more preferably 90%, and most preferably 95% homology to a reference amino acid sequence.
- the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids.
- sequence analysis software e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705.
- sequence analysis software e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705.
- the term “functional fragments” include those fragments of SEQ ID NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34, or other Neu family members that retain the function or activity of a Neu transcriptional regulator.
- One of skill in the art can screen for the functionality of a fragment by using the examples provided herein, where full-length Neu transcriptional factors are described. It is also envisioned that fragments of various Neu proteins that inhibit or promote transcription can be identified in a similar manner. Neu transcriptional activity can also be assayed by standard transcription assays.
- substantially identical is also meant an amino acid sequence which differs only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, etc.) or by one or more non-conservative substitutions, deletions, or insertions located at positions of the amino acid sequence which do not destroy the function of the protein assayed, (e.g., as described herein).
- such a sequence is at least 85%, more preferably identical at the amino acid level to SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34.
- substantially pure polypeptide is meant a Neu protein that has been separated from components which naturally accompany it.
- the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally occurring organic molecules with which it is typically associated.
- the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, Neu protein.
- a substantially pure Neu polypeptide can be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid encoding a Neu polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.
- a protein is substantially free of naturally associated components when it is separated from those contaminants that accompany it in its natural state.
- a protein that is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components.
- substantially pure polypeptides include those derived from eukaryotic organisms but synthesized in E. coli or other prokaryotes.
- polynucleotide molecules of the present disclosure can be expressed in a variety of prokaryotic and eucaryotic cells using regulatory sequences, vectors, and methods well established in the literature.
- Neu proteins produced according to the present invention can be purified using a number of established methods such as affinity chromatography using anti-Neu antibodies coupled to a solid support. Fusion proteins of antigenic tag and Neu can be purified using antibodies to the tag. Optionally, additional purification is achieved using conventional purification means such as liquid chromatography, gradient centrifugation, and gel electrophoresis, among others. Methods of protein purification are known in the art and can be applied to the purification of recombinant Neu described herein.
- hybrid proteins and hybrid Neu proteins containing one or more domains from another Neu family member are also contemplated. Such hybrid proteins facilitate structure-function analyses. Similarly, hybrid proteins allow for the alteration of Neu activity by increasing or decreasing the transcriptional regulation of target genes.
- Hybrid proteins of the present invention contain the replacement of one or more contiguous amino acids of the native Neu with the analogous amino acid(s) of Neu from another species or other protein of the Neu family.
- Such interspecies or interfamily hybrid proteins include hybrids having whole or partial domain replacements. Such hybrid proteins are obtained using recombinant DNA techniques well known by one of skill in the art.
- DNA molecules encoding the hybrid Neu proteins of interest are prepared using generally available methods such as PCR mutagenesis, site-directed mutagenesis, and/or restriction digestion and ligation.
- the hybrid DNA is then inserted into expression vectors and introduced into suitable host cells.
- Neu proteins can be used in immunoprecipitation to isolate interacting factors or used for the screening of interactors using different methods of two hybrid screening. Isolated interactors of Neu can be used to modify Neu activity or Neu can be used to modify the activity of interactors. Two hybrid screening has resulted in the isolation of several types of interactors. Sequence analyses showed that all interactors are novel proteins and contain RING-zinc finger domain located in the C-terminus of the protein. NeuI-1 (4 clones) is a novel splice variant (SEQ. ID.
- NeuI-3 (9 clones) has highest homology to a human hypothetical protein (GenBank accession number AK001459) and to a Drosophila hypothetical protein (AAF56052.2) produced from CG4813 gene of a genomic scaffold (GenBank accession number AE003740) (SEQ. ID. NOS.: 39, 40).
- NeuI-4 (12 clones) is the homolog of the androgen receptor coactivator ARA54 (SEQ. ID. NO.: 32; GenBank accession number AF060544) (SEQ. ID. NO.: 41, 42).
- synthetic peptides in still another embodiment, synthetic peptides, recombinantly derived peptides, fusion proteins, chiral proteins (stereochemical isomers, racemates, enantiomers, and D-isomers) and the like are provided which include a portion of Neu or the entire protein.
- the subject peptides have an amino acid sequence encoded by a nucleic acid which hybridizes under stringent conditions with an oligonucleotide of 15 or more contiguous nucleotides of SEQ. ID. NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33.
- Representative amino acid sequences of the subject peptides are disclosed in SEQ. ID. NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34.
- the subject peptides find a variety of uses, including preparation of specific antibodies and preparation of antagonists of Neu activity.
- non-human antisera or monoclonal antibodies e.g., murine, lagomorph, porcine, equine
- the production of non-human antisera or monoclonal antibodies is well known and can be accomplished by, for example, immunizing an animal with Neu protein or peptides.
- catalytic antibodies to nuclear isoforms of the Neu family of proteins or Neu protein metabolic intermediates that are transported into and out of the nucleus can be generated.
- antibody producing cells are obtained from immunized animals, immortalized and screened, or screened first for the production of the antibody that binds to the Neu protein or peptides and then immortalized. It can be desirable to transfer the antigen binding regions (e.g., F(ab′)2 or hypervariable regions) of non-human antibodies into the framework of a human antibody by recombinant DNA techniques to produce a substantially human molecule.
- the isolated or purified protein can be used to generate antibodies and tools for identifying agents that interact with the Neu protein and fragments of the Neu protein.
- the term “antibodies” can encompass polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. Antibodies that recognize Neu proteins and fragments of Neu proteins have many uses including, but not limited to, biotechnological applications, therapeutic/prophylactic applications, and diagnostic applications.
- various hosts including goats, rabbits, rats, mice, etc. can be immunized by injection with Neu proteins or any portion, fragment or oligopeptide that retains immunogenic properties.
- various adjuvants can be used to increase immunological response.
- adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol.
- BCG Bacillus Calmette-Guerin
- Corynebacterium parvum are also potentially useful adjuvants.
- Peptides used to induce specific antibodies can have an amino acid sequence consisting of at least three amino acids, and preferably at least 10 to 15 amino acids. Preferably, short stretches of amino acids encoding fragments of Neu proteins are fused with those of another protein such as keyhole limpet hemocyanin such that an antibody is produced against the chimeric molecule. While antibodies capable of specifically recognizing Neu proteins can be generated by injecting synthetic 3-mer, 10-mer, and 15-mer peptides that correspond to a protein sequence of Neu proteins into mice, a more diverse set of antibodies can be generated by using recombinant Neu proteins, purified Neu proteins, or fragments of Neu proteins.
- a substantially pure Neu protein or a fragment of Neu protein is isolated from a transfected or transformed cell.
- concentration of the polypeptide in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml.
- Monoclonal or polyclonal antibody to the polypeptide of interest can then be prepared as follows:
- Monoclonal antibodies to Neu proteins or a fragment of Neu proteins can be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Koehler and Milstein ( Nature 256:495-497 (1975), the human B-cell hybridoma technique (Kosbor et al. Immunol Today 4:72 (1983); Cote et al Proc Natl Acad Sci 80:2026-2030 (1983), and the EBV-hybridoma technique Cole et al. Monoclonal Antibodies and Cancer Therapy , Alan R. Liss Inc, New York N.Y., pp 77-96 (1985).
- Antibodies can also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al., Proc Natl Acad Sci 86: 3833-3837 (1989), and Winter G. and Milstein C; Nature 349:293-299 (1991).
- Antibody fragments that contain specific binding sites for Neu proteins can also be generated.
- fragments include, but are not limited to, the F(ab′) 2 fragments that can be produced by pepsin digestion of the antibody molecule and the Fab fragments that can be generated by reducing the disulfide bridges of the F(ab′) 2 fragments.
- Fab expression libraries can be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (Huse W. D. et al. Science 256:1275-1281 (1989)).
- monoclonal antibodies to Neu proteins or fragments thereof are made as follows. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein or peptides derived therefrom over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused in the presence of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued.
- HAT media aminopterin
- Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, E., Meth. Enzymol. 70:419 (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2.
- Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein or peptides derived therefrom described above, which can be unmodified or modified to enhance immunogenicity.
- Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and can require the use of carriers and adjuvant.
- host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable.
- An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991 (1971).
- Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19 in: Handbook of Experimental Immunology D. Wier (ed) Blackwell ( 1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 ⁇ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed.
- Antibody preparations prepared according to either protocol are useful in quantitative immunoassays that determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively (e.g., in diagnostic embodiments that identify the presence of a Neu protein in biological samples). It is also contemplated that various methods of molecular modeling and rational drug design can be applied to identify additional Neu protein family members, compounds that resemble a Neu protein or fragment or derivative thereof, and molecules that interact with Neu proteins and, thereby modulate their function.
- the Neu family of proteins presents an attractive set of diagnostic and therapeutic targets, considering the important regulatory role this family of proteins plays in the development function of adult organisms. This important role is reflected by the effects one or more defects in a mutant Neu protein can inflict upon an organism. Moreover, with the advances in the art of gene therapy, these defects can be corrected in utero or in early post-natal life or alternatively through the use of compounds identified in screening assays using Neu proteins.
- cancer cells or diseased cells or tissue
- the cancer cells can be treated in a manner to cause the over-expression of wild-type Neu protein to force differentiation and cease proliferation of the cancer cells. Accordingly, a method of treating cancer is similarly provided.
- neu family genes control cell proliferation and Ca 2+ signaling induced transcriptional processes, that manipulating Neu expression and function may be useful in controlling a variety of diseases, a few examples of which include depression, pain, anxiety, neurodegenerative diseases, and cancer.
- a mouse cDNA library of postnatal day (P) 1 brain (Stratagene, San Diego, Calif.) was screened with a mouse 0.7 kb EST (GenBank #AA5 18339) cDNA clone corresponding to a region ranging from about the translation initiation codon to the end of the first neuralized homology repeat domain (NHR1) of h-neu1 (Nakamura et al., 1998).
- FIG. 1 Sequence analyses, the results of which are shown in FIG. 1 , revealed that the isolated cDNA clones differed in their 5′ regions encoding muscle- and brain-specific m-Neu1 proteins with different N-termini ( FIG. 1 ).
- “A” shows an amino acid sequence comparison of Drosophila, human, rat and mouse neu1 proteins.
- Various domain regions of the proteins are illustrated.
- the regions Brain-N relating to the neural-specific N-terminal region, and Muscle-N, the muscle-specific N-terminal of mammalian neu proteins, are boxed.
- the NHR1 and NHR2 regions, neuralized homology repeat domains 1 and 2; RZD, RING zinc finger domain are underlined.
- NLS1 and NLS2, nuclear localization signal sequences are also shown.
- FIG. 1 RT-PCR analyses of RNA from mouse and rat brain and skeletal muscle resulted in identification of 6 different Neu1 transcripts in both species ( FIG. 1 ): 1) brain- and muscle-specific transcripts encoding Neu1 with the intact NHR2 domain (574 and 557 amino acids, respectively); 2) brain- and muscle-specific transcripts encoding Neu1 protein isoforms that lack the region between NHR1 and NHR2, the entire NHR2 region and different parts of the linker region preceding the RZD (Neu1- ⁇ NHR2A, 342 and 325 amino acids and Neu1- ⁇ NHR2B, 291 and 274 amino acids).
- the region between asterisks is absent in the splice isoform neu1- ⁇ NHR2A; the region between the open circles is absent in the splice isoform neu1- ⁇ NHR2B; the pKB consensus sequence between NHR1 and NHR2; LRS, two putative leucine rich sequences in the end of both the NHR; and SP, the serine and proline rich repeats between the NHR2 and RZD are boxed.
- “B” is a schematic representation of the domain structure of different mouse and rat Neu1 isoforms.
- m-Neu1 and r-Neu do not have sequences that are similar to the Lys-rich nuclear localization signal (NLS) in d-Neu.
- NLS Lys-rich nuclear localization signal
- HKAVKAR SEQ ID NO: 43
- RLKITKK SEQ ID NO: 44
- NHR1 and NHR2 contains also a putative protein kinase B/AKT phosphorylation site RPRSFT (SEQ ID NO: 45) which is similar to the respective consensus sequence RXRXXS/T (SEQ ID NO: 46). Datta, et al., Genes and Dev, 13:2905-27 (1999).
- the region between NHR2 and RZD of m-Neu1, r-Neu, and h-Neu contains two imperfect repeats of Pro, Ser, and Thr residues with the consensus sequence S/TXPXSPXSXPXSPXXXGXXX(X)SD (SEQ ID NO: 47) where X denotes any amino acid. It is interesting to note that this SP repeat of mammalian Neu1 proteins is not similar to any known protein motifs.
- RNase protection analyses was used to determine the levels of m-neu1 and r-neu1 mRNAs in the developing and adult brain and non-neural tissues ( FIG. 2 ).
- the cRNA probes used for detection of m-neu1 transcripts were complementary to a region encoding the muscle-specific ( FIG. 2 , left panel) or the brain-specific ( FIG. 2 , right panel) N-terminus and first half NHR1 of m-neu1. For r-neu1, the cRNA probe was complementary to a region encoding the second half of NHR2 up to the stop codon. Specific protected fragments are indicated on the right of each panel.
- FIG. 2 Bottom panels of FIG. 2 show the levels of GAPDH mRNA in the RNA samples.
- the nomenclature used to identify each sample is as follows: neu-M, indicates a muscle-specific m-neu1 transcript; neuB, indicates a brain-specific m-neu1 transcript; neu-B/M indicates the total pool of muscle- and brain-specific r-neu1 transcripts.
- E denotes “Embryonic day”
- P denotes “postnatal day”
- ad denotes “adult”
- th denotes “thymus”
- he denotes “heart”
- lu denotes “lung”
- sp denotes “spleen”
- ki denotes “kidney”
- li denotes “liver”
- mu denotes “skeletal muscle”
- gu denotes “gut”
- plac denotes “placenta”
- ctx denotes “cerebral cortex”
- cbl denotes “cerebellum”
- hc denotes “hippocampus”
- str denotes “striatum”
- mid denotes “ventral midbrain”
- hth denotes “hypothalamus”
- col denotes “colliculi”
- thal denotes “thalamus”
- pons denotes “pon
- neu1 mRNA The overall highest expression levels of neu1 mRNA were seen in the adult skeletal muscle and brain. In the skeletal muscle, neu1 mRNA levels were undetectable during embryonic development, low at birth and upregulated during postnatal development reaching the highest levels in the adult. Other non-neural tissues (heart, kidney, liver, lung, thymus, and spleen) except for the adult heart and testis did not express neu1 transcripts or the levels were below the detection limit of the RPA. In the brain, low levels of neu1 mRNA were detected at embryonic day (E) 13 and the expression increased progressively reaching the highest levels in the adult. neu1 expression levels were high in the cerebral cortex, hippocampus, and striatum and substantially lower in the olfactory system, thalamus/hypothalamus, midbrain, cerebellum, pons, and medulla.
- neu1 expression levels were specifically analyzed during postnatal development of cerebral cortex and cerebellum. In both of these brain regions, low levels of neu1 mRNA were observed in postnatal day (P) 1 whereas by two weeks after birth the expression levels increased significantly reaching the peak levels in the adult animal. High levels of neu1 mRNA expression were also detected in the adult dorsal root ganglia and moderate levels in the adult spinal cord. In all the tissues predominant neu1 transcripts contained intact NHR2 domain, whereas the levels the neu1 mRNAs lacking the NHR2 (neu1- ⁇ NHR1A and neu1- ⁇ NHR1B) were below 5% of all m-neu1 transcripts. Presented data show that neu1 is highly expressed during mouse and rat postnatal development and that the expression is confined to skeletal muscle and the nervous system.
- m-neu1 mRNA-specific labeling is shown at embryonic day 17 (E17, upper panel), at postnatal day 7 (P7, middle panel) and adult (AD, lower panel) in different brain structures. Exposure time was 3 weeks for adult and P7 sections and 6 weeks for E17 sections.
- BG denotes “basal ganglia”
- Cx denotes “cerebral cortex”
- Th denotes “thalamus”
- PTec denotes “pretectum”
- SC denotes “superior colliculi”
- IC denotes “inferior colliculi”
- Cb denotes “cerebellum”
- Me denotes “medulla”
- Pit denotes “pituitary”
- P denotes “pons”
- Hc denotes “hippocampus”
- Am denotes “amygdala”
- Pn denotes “Pontine nuclei”.
- the levels of neu1 mRNA increased significantly in the basal ganglia, amygdala, hypothalamus, and hippocampus. Low levels were present in the cerebral cortex and brainstem. In the adult, widespread expression of m-neu1 mRNA was observed throughout the brain particularly in the cerebral cortex, hippocampal formation, the basal ganglia, amygdaloid, hypothalamus, and pontine nuclei and in the cerebellum, while lower levels were seen in the mesencephalon and medulla oblangata. m-neu1 mRNA-specific signal was not detected in most of the thalamic nuclei.
- FIG. 4 shows the results of an in situ hybridization analysis of neu1 mRNA expression in adult rat brain.
- the coronal sections (A-H) correspond to the levels from 5 Bregma in the atlas of Paxinos and Watson (Paxinus and Watson, 1986) as indicated by numbers in the left part of the bottom of each autoradiograph.
- CTX denotes “cerebral cortex”
- CPu denotes “caudate putamen”
- Pir denotes “piriform cortex”
- LS denotes “lateral septum”
- HDB denotes “nucleus of the horizontal limb of the diagonal band of Broca”
- VDB denotes “nucleus of the vertical limb of the diagonal band of Broca”
- GP denotes “globus pallidus”
- BSTM and BSTL denotes “bed nucleus of the stria terminalis, medial and lateral division respectively”
- MHb denotes “medial habenular nucleus”
- Rt denotes “reticular thalamic nucleus”
- AH denotes “anterior hypothalamic area”
- Zi denotes “zona incerta”
- Am denotes “amygdaloid nuclei”
- VMH denotes “ventromedial hypothalamic nucleus”
- DMD
- FIG. 5 shows expression of neu1 mRNA in an adult rat nervous system.
- Dark-field in situ hybridization autoradiographs showing labelling in A, the cerebral cortex; B, CA1-CA3, hippocampal subfields, and in the dentate gyrus (DG) including the strata molecular (Mol), lacunosum molecular (Lmol) and radiatum (Rad); C, substantia nigra compact part (SNc) and reticular part (SNr); D, medial habenular nucleus (MHb); E, locus coeruleus (LC); F, in the molecular (Mol) and granular (Gr) layer of cerebellar cortex; G, in the layers of the retina: ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), pigmental epitelial (PE); H, dorsal root ganglia (DRG).
- FIG. 6 shows cellular localization of neu1 mRNA in an adult rat nervous system.
- A in the layer II of the cerebral cortex at the level of the somatosensory cortex (CTX);
- B dentate gyrus (DG) of hippocampus;
- C CA3 layer of the hippocampus;
- D polymorph layer of dentate gyrus (PoDG);
- E lateral septum (LS);
- F substantia nigra compact part (SNc); G, globus pallidus (GP); H and I, spinal cord at L3 level, respectively in the layers 9 and 2-3 (Sc);
- J dorsal root ganglia (DRG);
- K glia limitans (GL);
- L pineal gland
- G the cells in the globus pallidus (GP) do not express neu1 mRNA.
- Mol stratum moleculare
- Hil hilus of the hippocampus
- Rad stratum radiatum
- Or stratum oriens.
- the scale bar corresponds to 25 ⁇ m in length.
- r-neu1 cRNA was detected in caudate putamen and accumbens but not in the globus pallidus ( FIG. 4A , B, 6 G).
- Moderate to high levels of neu1 mRNA were seen in all the amygdaloid nuclei ( FIG. 4C -D), the interstitial nucleus of the posterior limb of anterior commissure and the bed of stria terminalis of extended amygdala ( FIG. 4B ).
- high levels of labeling were seen in the cells of lateral septum ( FIG. 4A ; 6 E), and very low levels in the vertical and horizontal limb of the diagonal band of Broca.
- the supraoptic, suprachiasmatic, supramammilary, and ventromedial nuclei expressed moderate levels, and several other nuclei expressed low levels of neu1 mRNA ( FIG. 4B -E).
- the medial habenula expressed high levels of neu1 mRNA, while moderate levels were observed in the reticular thalamic nucleus and low levels in a few other nuclei of the thalamus, such as the zona incerta, lateral habenula, mediodorsal thalamic nuclei, laterodorsal thalamic nuclei, paraventricular thalamic nucleus, rheuniens, rhomboid thalamic nuclei, and medial pretectal nucleus (Table 1, FIG.
- the locus coeruleus, and the pontine, trapezoid body, facialis, pontine reticular, and rostroventrolateral reticular nuclei were labeled with moderate density with r-neu1 cRNA (Table 1, FIG. 4F, 5E ). Beyond this, there was low-density labeling in the trigeminal, facial, solitary, and hypoglossal nuclei ( FIG. 4G , H). In addition, neu1 cRNA labeling was evident at low levels or in association with fewer cells in several other nuclei, such as the vestibular, cochlear, paragigantocellular, and abducens nuclei (Table 1).
- m-neu1 mRNA expression was predominant in cells displaying neuronal profile (large cells with weakly stained nuclei) and not in the cells with glial profile (small cells with strongly stained nuclei).
- neu1 mRNA expression was not detected in the white matter, where neuronal cells are absent.
- One of the few exceptions of non-neuronal neu1 mRNA expression was glia limitans that displayed dense labeling ( FIG. 6K ).
- FIG. 7 shows the results of neuronal expression studies of neu1 mRNA levels in adult rat brain
- neu1 mRNA was visualized as autoradiographic grains whereas NeuN was shown as peroxidase staining resulting in a yellow color. The two labelings co-localized with all the cells.
- A layer II of cerebral cortex (CTX); B, CA1 layer of the hippocampus; C, polymorph layer of the dentate gyrus (PoDG) and CA3 layer of the hippocampus; D, caudate putamen (CPu); E, reticular thalamic nucleus (Rt); and F, ventromedial hypothalamic nucleus (VMH), were studied Note that neurons (NeuN-positive cells) of the ventral posterolateral thalamic nucleus (VPL) in E do not express neu1 mRNA.
- C layer II of cerebral cortex
- C polymorph layer of the dentate gyrus
- CPu caudate putamen
- E reticular thalamic nucleus
- VPL ventromedial hypothalamic nucleus
- the levels of neu1 mRNA are significantly downregulated in the granular and molecular layers of dentate gyrus of adult rat brain at 24 hours after the treatment with kainic acid (B and B1), as compared to control brains (A and A1).
- Regions analyzed are denoted as follows: CTX, cerebral cortex; DG, dentate gyrus; Am, amygdala; Pir, piriform cortex; VMH, ventromedial hypothalamic nucleus; and Mol, for the molecular layer of the hippocampus. Particularly pronounced was the reduction of labeling in the molecular layer of the dentate gyrus. Similarly, but less consistently, a down-regulation of neu1 mRNA was observed in the cerebral cortex.
- m-Neu1 The ability of m-Neu1 to act as a transcriptional regulator was studied using a chloramphenicol acetyl-transferase (CAT) assay.
- CAT chloramphenicol acetyl-transferase
- m-Neu1 on transcriptional activity was studied using a chloramphenicol acetyl-transferase (CAT) assay and the following promoters: 1) TATA-box containing: 1.0 kb BDNF-I-CAT, 0.3 kb BDNF-II-CAT, 0,7 kb BDNF-IV CAT, 0.4 kb NF-L, 1.0 kb GAP-43, 2) TATA-less promoters with putative initiators (Inr): 0.4 kb BDNF-III-CAT, 0.4 kb LNGFR-CAT, and 0.3 kb ME1-CAT.
- CAT chloramphenicol acetyl-transferase
- FIG. 9 show that Neu1 represses transcription from various promoters in transient expression assays.
- the data for this figure was gathered from Neuro2A cells that were co-transfected with 0.5 ⁇ g of various reporter plasmids containing different promoters driving the epression of CAT and pRcCMV expression plasmid (1.0 ⁇ g) without any cDNA sequence (control) or containing m-neu1 cDNAs encoding the full length protein (neu-FL) or the m-Neu-1- ⁇ NHR2A (neu ⁇ NHR2A) isoform lacking the region between NHR1 and RZD, using FuGENE-6 transfection system.
- the pON260 expression plasmid (0.1 ⁇ g) encoding ⁇ -galactosidase was included in the transfections to normalize the transfection efficiencies.
- the CAT activity is defined as 100 for each reporter when cotransfected with the pRcCMV parental expression plasmid.
- the CAT activities are expressed relative to the value obtained by cotransfection of each reporter plasmid and the parental pRcCMV expression plasmid.
- the data shown are representative of at least three independent experiments. Error bars represent the S.E.
- BDNF-I 1.0 kb BDNF promoter I, BDNF II, 0.3 kb BDNF promoter II; BDNF III, 0.4 kb BDNF promoter III; BDNF IV, 0.7 kb BDNF promoter IV; NF-L, 0.4 kb NF-L promoter; GAP-43, 1.0 kb GAP-43-promoter, LNGFR, 0.4 kb LNGFR promoter; ME1, 0.3 kb ME1 promoter.
- FIG. 10 shows that neuralized homology repeat domains of Neu1 mediate the transcriptional repression when fused to the DNA binding domain of Gal4.
- Neuro2A cells were cotransfected with Gal4TK-CAT reporter plasmid containing five Gal4 binding sites in front of TK promoter driving the expression of CAT (0.5 ⁇ g) and pBIND expression plasmid (1.0 ⁇ g) without any cDNA sequence (G4) or containing different regions of m-neu1 cDNA fused in-frame to Gal4 DNA-binding domain using FuGENE-6 transfection system.
- the designations of the constructs are shown on the left of FIG. 10 .
- the CAT activities are expressed relative to the value obtained by cotransfection of the reporter plasmid and the parental pRcCMV expression plasmid which was set 100.
- the data shown are representative of at least three independent experiments. Error bars represent the S.E.
- NHR1 and NHR2 domains possess transcriptional repressor activity whereas neural and muscle-specific N-termini (amino acids 1-60), RZD (amino acids 509-574) and the serine-proline rich linker region joining RZD to NHR2 (amino acids 439-510) did not affect transcription ( FIG. 10 ).
- m-Neu1 acts as a transcriptional repressor when tethered to a promoter via a heterologous DNA binding domain (DBD).
- DBD heterologous DNA binding domain
- Neu1 as a transcriptional repressor implies its nuclear localization.
- a putative lysine rich nuclear localization signal (NLS) that is present in d-Neu protein (d-NLS) is not conserved in mammals. Boulianne et al., EMBO J, 10:2975-2983 (1991) and Price et al., EMBO J, 12:2411-2418 (1993).
- d-NLS d-Neu protein
- FIG. 11 This figure shows the subcellular localization of m-Neu1-FLAG and m-Neu1-EGFP fusion proteins in Neuro2A cells.
- Neuro2A cells were transfected expression plasmids encoding m-Neu1-FLAG (A, E, F) and different m-Neu1-EGFP (B, C, D) fusion proteins or with parental pFLAG (G) and pEGFP-C3 (H) expression plasmids. Numbers indicate the amino acids of Neu1 fused to the C-terminal of FLAG and EGFP.
- A shows the Neu1-FLAG fusion protein is localized either in the cytoplasm or in the nucleus;
- B shows that Neu1/120-EGFP fusion protein containing amino acids 1-120 of Neu1 exhibits constitutive nuclear localization in all cells;
- C shows that the Neu1-60/120-EGFP fusion protein is seen exclusively in the nucleus revealing that the first 60 amino acids of NHR1 are sufficient for nuclear localization of Neu1;
- D the Neu1-1/60-EGFP fusion protein containing the N-terminal 60 amino acids of the brain- specific isoform of m-Neu1 shows localization that is identical to H, localization of EGFP synthesized from the parental pEGFP-C3 expression plasmid;
- E inhibition of nuclear export of Neu1-FLAG fusion protein by treatment of Neuro2A cells with leptomycin B (10 ng/ml) for 12 hours or
- F 2 days of RA and dBcAMP mediated differentiation leads to predominant nuclear localization of Neu1-FLAG fusion protein;
- the fusion protein m-Neu1-FLAG comprised of the full-length m-Neu1 with N-terminal FLAG tag showed either predominantly nuclear ( ⁇ 40% of the positive cells) or predominantly cytoplasmic ( ⁇ 60% of the positive cells) distribution. If localized in the cytoplasm, m-Neu1-FLAG fusion protein was observed in the form of granular speckles in the perinuclear area, in the vicinity of plasma membrane and in neurites ( FIG. 11A ).
- m-Neu1 does not have sequences that are similar to the lysine-rich d-NLS, however, two smaller clusters of arginine and lysine rich amino acids (HKAVKAR (SEQ ID NO: 43) at 80-85 and RLKITKK (SEQ ID NO: 44) at 107-113) are present in the NHR1 of m-Neu1 ( FIG. 1 ).
- HKAVKAR SEQ ID NO: 43
- RLKITKK SEQ ID NO: 44
- m-Neu1 protein contains two putative leucine-rich sequences, one in the end of each of the NHR ( FIG. 1 ), that are similar to the identified NES in different proteins.
- LMB Yamaga et al., J Biol Chem, 274:28537-28541 (1999).
- FIG. 11F the number of cells with nuclear localization of m-Neu1-tagged protein increased substantially (from 45% to 80%) 12 hs after the RA- and cAMP-mediated neuronal differentiation. It suggests that neuronal differentiation changes the mechanisms that are responsible for the translocation of m-Neu1 protein in Neuro2A cells.
- SEQ. ID. NOS. human neu2 cDNA of SEQ. ID. NO.:21; human neu2 alternatively spliced form h-neu2- ⁇ NHR1 of SEQ. ID. NO.:23; human neu2 alternatively spliced form h-neu2- ⁇ NHR2 of SEQ. ID. NO.:25; rat neu2 cDNA SEQ. ID. NO.: 27; human neu3 cDNA of SEQ. ID. NO.: 29; mouse neu3 cDNA of SEQ. ID.
- Corresponding peptide sequences are presented as SEQ. ID. NOs: human Neu2 protein of SEQ. ID. NO.: 22; human Neu2 alternatively spliced form h-neu2- ⁇ NHR1 of SEQ. ID. NO.:24;; human Neu2 alternatively spliced form h-neu2- ⁇ NHR2 of SEQ. ID. NO.:26; rat Neu2 protein SEQ. ID. NO.: 28; human Neu3 protein of SEQ. ID. NO.: 30; mouse Neu3 protein of SEQ. ID. NO.: 32; and human Neu4 protein (partial) of SEQ. ID. NO.: 34. All the mammalian Neu proteins show significant homology in the NHR and Ring zinc finger domains.
- FIG. 12 Alignment of neuralized homology motifs of human Neu1, Neu2, and Neu3 proteins is shown in FIG. 12 .
- Amino acid sequence comparison of the neuralized homology regions (NHR) of Drosophila neu and human neu1, neu2 and neu3 proteins is shown in FIG. 12 .
- Amino acids that are identical in human and Drosophila neu proteins are highlighted in white on black background.
- Amino acids that are similar in human and Drosophila neu proteins are boxed and highlighted on grey background.
- neu1 mRNA is highest in adult, mature neurons ( FIG. 2-7 ).
- neu2 in contrast to neu1 is expressed at high levels already in the embryonic brain and the expression levels decrease during postnatal development ( FIG. 13 ).
- Total RNA was isolated from the indicated mouse and rat brain regions and non-neural tissues and the levels of neu2 transcripts were analyzed by RNase protection assays. cRNA probes that were used for detection of neu2 transcripts covered the region encoding the NHR1 of rat neu2. Specific protected fragments are indicated on the left of the panel.
- E Embryonic day; P, postnatal day; ad, adult; HC, hippocampus; CTX, cerebral cortex; OLF, olfactory bulb; STR, striatum; THA, thalamus; HTH, hypothalamus; COL, colliculi; MID, ventral midbrain; CBL, cerebellum; PONS, pons; MED, medulla;SP.C, spinalcord; PIT, pituitary; MUS, muscle; SPLCE, spleen tRNA, yeast tRNA as a negative control.
- E Embryonic day; P, postnatal day; AD, adult; HC, hippocampus; CTX, cerebral cortex; OLF, olfactory bulb; STR, striatum; THA, thalamus; COL, colliculi; MID, midbrain; CBL, cerebellum; PONS, pons; MED, medulla; LIV, liver; HEA, heart; KID, kidney; LUN, lung; MUS, muscle; SPL, spleen; TES, testis; THY, thymus; tRNA, yeast tRNA as a negative control.
- rat brain library was screened using a yeast two hybrid system with a mouse Neu1 protein as a ligand with which to isolate and identify proteins that interact with Neu1. Fifty-three (53) clones were isolated. cDNAs that yielded more than 1 clone were sequenced and identified as four interactors: NeuI-1, NeuI-2, NeuI-3, and NeuI-4.
- NeuI-1 (4 clones) is a novel splice variant (SEQ. ID. NO.: 29) of zinc finger protein Miz1/PIASX/ARIP3 (GenBank accession number NM — 008602; AF077953; AF077954; AF044058).
- NeuI-2 (3 clones) is a fourth homologue (SEQ. ID.
- GenBank accession number AF277171; AF302084) of zinc finger protein ZNF127 (GenBank accession number U19106; U19107), NeuI-3 (9 clones) has highest homology to a human hypothetical protein (GenBank accession number AK001459) and to a Drosophila hypothetical protein (AAF56052.2) produced from CG4813 gene of a genomic scaffold (GenBank accession number AE003740) (SEQ. ID. NO.: 31), and NeuI-4 (12 clones) is the homologue of the androgen receptor co-activator ARA54 (SEQ. ID. NO.: 32; GenBank accession number AF060544).
- E Embryonic day; P, postnatal day; ad, adult; cbl, cerebellum; ctx, cerebral cortex; stem, brainstem; hc, hippocampus; hc+KA, hippocampus from rats treated for 4h with the glutamate receptor agonist kainic acid; hea, heart; kid, kidney; mus, skeletal muscle; spl, spleen; thy, thymus; tes, testis; li, liver; lu, lung; tRNA, yeast tRNA as a negative control.
- Neu1 interactors were expressed in the brain and skeletal muscle, tissues where neu1 mRNA is predominantly expressed. This suggests that neuI-1-neuI-4 interact with Neu 1 protein and modify its activity in vivo.
- Neu1 as a calcium-dependent transcriptional repressor was studied by transfecting Neuro2A cells with m-neu1-CMV expression vector. This system was used to examiner whether or not Neu1 could suppress transcription of IEGs in response to the simultaneous stimulation of cells with calcium, ionophore A23187, and forskolin. As a combination of forskolin with calcium, ionophores leads to increased c-fos mRNA levels in Swiss 3T3 cells (Mehmet H, 1990).
- m-Neu1 affects a variety of target gene promoters in transient transfection assays
- m-Neu1 functions by interfering directly with the function of Pol II complex, particularly suppressing the TBP transcriptional activity.
- m-Neu-CMV expression constructs were cotransfected together with m-TBP-CMV.
- tk thymidine kinase
- a biopsy is obtained from a subject possibly suffering from a neoplastic disease, such as an astrocytoma. Following excision of the sample, the tissue is immediately minced and quickly frozen in liquid nitrogen. A sample 1 gram sample of tissue is then ground with a prechilled mortar and pestle for suspension. The ground tissue is then suspended in approximately 1.2 ml of digestions buffer (100 mM NaCl, 10 mM Tris-Cl, pH 8.0, 25 mM EDTA, pH 8.0, 0.5% (w/v) SDS, and 0.1 mg/ml proteinase K, which is added fresh for each use). Samples are shaken and incubated for 12 to 18 hours at 50° C.
- digestions buffer 100 mM NaCl, 10 mM Tris-Cl, pH 8.0, 25 mM EDTA, pH 8.0, 0.5% (w/v) SDS, and 0.1 mg/ml proteinase K, which is added fresh for each use.
- the samples are extracted with an equal volume of phenol/chloroform/isoamyl alcohol, to remove proteinatious material. Centrifuge the mixture for 10 minutes at 1700 ⁇ g. If phases do not resolve well, add another volume of digestion buffer, omitting proteinase K, and repeat centrifugation. Repeat the extraction until no thick white material appears at the interface. Transfer the top aqueous layer to a new tube.
- the purified DNA is analyzed for the presence or mutation of a wild type copy of a neu family gene using Southern Blotting and sequencing. The absence or mutation of such in the subject indicates the presence of a malignancy.
- a tissue sample is obtained from a subject possibly suffering from a neoplastic disease.
- the biopsy is removed and cut into less than 2 gram pieces. These pieces are quick-frozen in liquid nitrogen.
- Twenty (20 ml) of tissue guanidinium solution is used to process 2 grams of tissue.
- the tissue guanidinium solution is prepared by dissolving 590.8 grams of guanidinium isothiocyanate in approximately 400 ml DEPC-treated H 2 O. To this is added 25 ml of 2M Tris-Cl, pH 7.5 (0.05 M final) and 20 ml of 0.5 M Na 2 EDTA, pH 8.0 (0.01 M final). Stir overnight, adjust the volume to 950 ml, and filter. Finally, add 50 ml 2-ME.
- tissue guanidinium solution is added to the tissue, the sample is immediately ground in a tissuemizer with two or three ten second bursts. Following disruption, the solution is subjected to centrifugation for 10 minutes at 12,000 ⁇ g in a SS-34 rotor, at 12° C. To the supernatant is added 0.1 volumes of 20% Sarkosyl. This mixture is then subjected to heat at 65° C., for 2 minutes.
- RNA pelleted contained therein is placed in a 50-ml plastic tube.
- tissue resuspension buffer Three (3) ml of tissue resuspension buffer and allow pellet to resuspend overnight or longer at 4° C. Extract solution sequestially with 25:24:1 phenol/chloroform/isoamyl alcohol, then with 24:1 chloroform/isoamyl alcohol.
- Extract solution sequestially with 25:24:1 phenol/chloroform/isoamyl alcohol, then with 24:1 chloroform/isoamyl alcohol.
- Add 0.1 volume of 3 M sodium acetate, pH 5.2, and 2.5 volume of 100% ethanol precipitate, and resuspend RNA in water.
- the sample is quantitated and analyzed for the expression of the neu family of genes. Samples with aberent expression levels indicate the presence of neoplastic cells.
- Cells are isolated from a subject to be transfected with a construct encoding Neu protein (Neu construct).
- the Neu construct is transfected using DEAE-dextran.
- the cells are seeded in 6-well tissue culture plates and are transfected with a total of 1-2 ⁇ g of total DNA containing the Neu contruct. After 5 hours, 1 ml of DMEM containing 20% fetal bovine serum is added and the cells are allowed to incubate overnight.
- Expression of Neu is then determined using immunoprecipitation with an antibody-agarose conjugate (8 ⁇ g) plus 25 ⁇ l of a 50% slurry of Protein A-agarose. Immune complexes are washed in a wash buffer (20 mM Hepes, pH 7.4, 10 mM MgCl 2 , and 1 mM DTT). The immune complexes are placed in a denaturing protein sample buffer that separated the antibody from any bound antigen. The protein samples are then run on SDS-polyacrylamide gel electrophoresis to detect the expression of a target Neu protein.
Abstract
The disclosure relates to isolated polynucleotides and purified polypeptides of the Neu family of proteins, which have been shown to demonstrate transcriptional regulatory activity. For example, the purified polynucleotide can encode a Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. A purified Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. Antibodies capable of specifically binding to the disclosed Neu polypeptides are disclosed. Vectors expressing the disclosed Neu protein coding regions and host cells containing the vectors are disclosed. Methods of making the Neu proteins disclosed are also provided, as are method of identifying binding partners that interact with a Neu protein family member.
Description
- 1. Field of the Invention
- The described invention relates to the family of mammalian Neuralized (neu) genes, proteins encoded by those genes (Neu), expression patterns of the gene family, their function as a transcriptional regulator, and the proteins with which the Neu family of proteins interacts. Additionally, therapeutic and diagnostic uses for the Neu family of proteins and agents that bind thereto are also provided.
- 2. Description of the Related Art
- Development and functioning of the nervous system requires orchestrated action of thousands of transcriptional regulators. Balance between transcriptional activators and repressors determines the spectrum of expressed genes. The molecular basis of the initial stages of neurogenesis as well as several aspects of neuronal differentiation have been extensively studied. As a result, a variety of transcriptional activators and repressors have been discovered and characterized. Our understanding of these systems and their component interactions, however, is far from complete. Little is known about the molecular mechanisms that support neuronal circuits in developing and mature nervous systems or the molecular mechanisms that coordinate maintenance of the differentiated state.
- The process of lateral inhibition prevents neighboring cells from developing into the same type of differentiated cells in flies and in vertebrates. Tanabe & Jessell, Science, 274:1115-23 (1996). In Drosophila, a group of mutations has been described that shows severe defects in the process of lateral inhibition in the developing nervous system. These neurogenic mutations result in hyperplasia of the neural tissue at the expense of epidermal structures. Campos-Ortega & Jan, Annu Rev Neurosci, 14:399-420 (1991). The temporal and spatial expression patterns of the neu are compatible with its function as a neurogenic gene in Drosophila. The Neu protein is expressed throughout the ectoderm at the time when cell fate is determined and its expression proceeds in neuroblasts. Boulianne, et al., EMBO J, 10:2975-2983 (1991). neu expression has been detected in actively proliferating neuroblasts in several regions of the CNS and PNS. Expression of neu in imaginal disc suggests that it is also involved in later stages of development. The neu gene encodes a RING finger (C3HC4) type zinc finger protein. The molecular function of the Drosophila Neu protein is unknown. Interestingly, it was discovered that EST data bases contain a homologue of Neu suggesting that a family of Neu-like proteins is present in Drosophila.
- Current studies of the brain development in Drosophila and vertebrates, indicate that many basic molecular and genetic mechanisms involved in neurogenesis are highly conserved. During development of the nervous system, neural cell specification is acquired through the series of progressive restrictive steps. In Drosophila, neural precursors are first specified by proneural genes including basic helix-loop-helix (bHLH) transcription factors of atonal and achaete-scute complex. Simpson, Neuron, 15:739-742 (1995). The process of lateral inhibition, which further restricts the developmental potential of neuroectodermal cells is regulated by neurogenic genes such as Notch, mastermind, big brain, Delta, Enhancer of split, and neuralized. Analysis of the function of these neurogenic loci in the Drosophila embryo has revealed that mutations in any of these genes result in hyperplasia of neural tissue at the expense of epidermal structures and also cause defects in tissues derived from mesoderm and endoderm. Campos-Ortega and Jan, Annu. Rev Neurosci, 14:399-420 (1991); Harentstein et al., Development, 116:1203-1220 (1992). Vertebrate homologues of Notch, Delta and the proneural/neurogenic genes of atonal, achaete-scute, hairy, and Enhancer of Split complex have been identified and recent work, mostly in Xenopus and mouse, suggests that their role in neurogenesis is conserved. Lewis, Curr Opin Neurobiol, 6:3-10 (1996); Kageyama et al., Int J Biochem Cell Biol, 29:1389-1399 (1997); and Beatus, Lendahl, J Neurosci Res 54:125-136 (1998). For example, postnatal Notch signaling affects the elaboration of different body systems and regulates plasticity of cortical postmitotic neurons. Artavanis-Tsakonas et al., Science, 284:770-776 (1999); Redmond et al., Nat Neurosci, 3:30-40 (2000); and Sestan et al., Science, 286:741-746 (1999).
- The last few years have brought the identification and characterization of many new key regulators of vertebrate neurogenesis. Recently, a human homologue of Drosophila Neu gene was isolated and its expression in the adult nervous system and in tumors of neuroectodermal origin, such as astrocytomas, was characterized. Nakamura, et al., Oncogene 16(8):1009-1019 (1998). Nakamura and others (1998) hypothesized that h-neu1 plays a role in determination of cell fate in the central nervous system and may act as a tumor suppressor which inactivation could be associated with malignant progression of astrocytic tumors. A homology search in human, rat, and mouse EST databases revealed three new mammalian Neu homologs, suggesting that a family of Neu-like proteins exists in mammals.
- The disclosure relates to isolated polynucleotides and purified polypeptides of the Neu family of proteins, which have been shown to demonstrate transcriptional regulatory activity. For example, the purified polynucleotide can encode a Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. A purified Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. Antibodies capable of specifically binding to the disclosed Neu polypeptides are disclosed. Vectors expressing the disclosed Neu protein coding regions and host cells containing the vectors are disclosed. Methods of making the Neu proteins disclosed are also provided, as are methods of identifying binding partners that interact with a Neu protein family member.
-
FIG. 1 shows the primary structure of neu1 protein isoforms in mouse and rat. -
FIG. 2 is an analysis of neu1 mRNA expression by RNase protection assay in mouse and rat. -
FIG. 3 is an in situ hybridization analysis of neu1 mRNA expression in the developing and adult mouse brain. -
FIG. 4 is an in situ hybridization analysis of neu1 mRNA expression in adult rat brain. -
FIG. 5 shows expression of neu1 mRNA in an adult rat nervous system. -
FIG. 6 shows cellular localization of neu1 mRNA in an adult rat nervous system. -
FIG. 7 shows the combined analyses of in situ hybridization of neu1 mRNA and immunohistochemistry of the neuronal marker neuN. -
FIG. 8 shows neu1 mRNA expression in the hippocampus of adult rat brain after kainic acid treatment. -
FIG. 9 shows transcriptional analysis from various promoters in transient expression assays. -
FIG. 10 shows that neuralized homology repeat domains of neu1 mediate the transcriptional repression when fused to the DNA binding domain of Gal4. -
FIG. 11 shows the subcellular localization of neu-FLAG and neu-EGFP fusion proteins in Neuro2A cells, using FLAG immunofluorescence using anti-FLAG antibody (A, E, F, G) and direct fluorescence of EGFP fusion proteins (B, C, D, H). -
FIG. 12 shows alignment of neuralized homology repeat domains of human Neu1, Neu2, and Neu3 proteins. -
FIG. 13 shows the analysis of neu2 mRNA expression by RNase protection assay in mouse and rat. -
FIG. 14 shows the analysis of neu3 mRNA expression by RNase protection in mouse. -
FIG. 15 is an analysis of the expression of rat Neu1 interactors by RNase protection assay. - The invention described herein relates to the identification of members of the Neuralized (neu) family of genes and their respective proteins, and aspects of their structure and function as transcriptional regulators. The invention relates to the characteristics of mammalian neu gene family's conserved structural motifs, related function as transcriptional regulators, and functional features of the family relating to expression patterns and potential interactions with interaction-partners, providing tools with which to explore the Neu-related regulatory cascades that operate in neurons and other cell types.
- Structure
- The invention described herein relates to the neuralized (Neu) family of transcriptional regulators that contain a C-terminal C3HC4 RING zinc finger and at least one neuralized homology repeat domain. The term “neuralized” (or “Neu”), as used herein, includes all members of the Neu family such as Neu1, Neu2, Neu3, Neu4 coding sequences and proteins. These proteins belong to a family of proteins that share C-terminal C3HC4 RING zinc finger and at least one neuralized homology repeat domain. Neuralized homology repeat domains represent a novel class of transcription repression domains that regulate transcription of a large number of genes.
- The C3HC4 RING-zinc finger motif is a cystine-rich amino acid sequence motif found in the sequence of the human RING gene. Freemont, et al., Biochem J, 278:1-23 (1991); Freemont, Ann NY Acad Sci, 684:174-192 (1993). The motif can be described as C—X2—C—X(9-27)—C—X(1-3)—H—X2—C—X2—C—X(4-48)—C—X2—C, where C is a cysteine, H is a histamine, and X can be any amino acid. This family includes genes that are involved in the regulation of development, differentiation, apoptosis, oncogenesis, and membrane trafficking.
- Several isolated and characterized RING-zinc finger proteins have proposed roles in gene regulation. Although the precise function of the RING-zinc finger domain is unknown, indirect data demonstrates that the RING-zinc finger domain could function as a DNA-binding or protein-protein interaction domain. These two functions are related. Several transcriptional repressors which act as dimers have been characterized. Their structures comprise both dimerization and DNA-binding surfaces. For example, well known transcriptional regulators that contain RING-zinc finger domains are BRCA1 (Miki et al., Science, 266(5182):66-71 (1994)) and MEL18 (Kanno et al., EMBO J. 15;14(22):5672-8 (1995)), a polycomb group-related transcriptional regulator.
- Function and Interactions
- Neu Function as a Transcriptional Regulator
- Mammalian Neu1 acts as a powerful transcriptional repressor in transient expression assays and silences both, TATA-containing and TATA-less promoters, including the promoters of NGF, BDNF, NF-L, and GAP-43. NHRs function as transcription repression domains, suggesting that NHR-containing proteins represent a novel class of transcriptional repressors. It is likely that mammalian Neu1 mediates transcriptional repression through protein-protein interactions. Like several known repressors, mammalian Neu1 could function through interaction with co-repressors such as dCtBP or mammalian homologues of Groucho, and general repressor complexes, such as NC2, Mot1, or Not to interfere with the function of Pol II complex. Maldonado et al., Cell, 99:455-458 (1999) and Mannervik et al., Science, 284:606-609 (1999). Alternatively, repression could be achieved through chromatin remodeling by recruiting the histone deacetylase complexes (HDACs). Glass and Rosenfeld, Endocr Rev, 21:447 (2000); Knoepfler and Eisenman, Cell, 99:447-450 (1999); and Torchia et al., Curr Opin Cell Biol, 10:373-383 (1998). Current data suggest that the mechanism of Neu1 repression does not include a HDAC complex in neuroblastoma Neuro2A cells, as the HDAC inhibitor trichostatinA did not relieve m-Neu1-mediated repression in these cells.
- Neu is a Shuttling Protein with Dominant Cytoplasmic Localization as a Result of a Nuclear Import Combined with an Efficient Export
- A putative nuclear localization signal has been identified in the N-terminus of d-Neu, however, the NLS sequence identified in d-Neu, is not conserved in mouse, rat and human Neu proteins. Boulianne et al., EMBO J 10:2975-2983 (1991) and Price et al., EMBO J, 12:2411-2418 (1993). The weak NLS sequences (HKAVKR (SEQ ID NO: 43), RLKITKK (SEQ ID NO: 44)), that were identified in mammalian Neu1 proteins, have been suggested to regulate nuclear import of a fraction of the synthesized protein. Boulikas, J Cell Biochem, 60:61-82 (1996). Indeed, m-Neu1 resides both in the cytoplasm and in the nucleus, revealing that it is the subject of regulated nuclear import. Recent studies have shown that importin-α family members are involved in the formation of the NLS receptor complexes that govern the protein transport to the nucleus. Ullman et al., Cell, 90:967-970 (1997); and Izaurralde and Adam, RNA, 4:351-364 (1998). Interestingly, importin-α3 was identified here as one of the m-Neu interacting proteins by yeast two-hybrid screening. Furthermore, the results discussed herein also demonstrate that the CRM1/exportin1-related export pathway controls the nucleocytoplasmic shuttling of Neu1, since the nuclear export of a tagged-m-Neu1 fusion protein is blocked by LMB. LMB is a microbial metabolite that inactivates the nuclear export by interfering with the binding of CRM1/exportin1 to the nuclear export signals. Fornerod et al., Cell, 90:1051-1060 (1997); Kudo et al., Exp Cell Res, 242:540-547 (1998); Kudo et al., Proc Natl Acad Sci USA, 96:9112-9117 (1999); Fukuda et al., Nature, 390:308-311 (1997); and Nishi et al., J Biol Chem, 269:6320-6324 (1994). These data reveal that mammalian Neu1 function is additionally regulated by nucleocytoplasmic shuttling.
- Neu Function as a Calcium-Signal Transducer
- Transcriptional activity of Neu is controlled by calcium (Ca2+) signaling that regulates Neu translocation into the nucleus where Neu acts as a transcriptional repressor. It has been long known that intracellular calcium controls a variety of brain- and muscle cell functions. Since Ca2+ levels regulate nucleocytoplasmic shuttling of transcription factors (Crabtree, Cell, 96:611-614 (1999)), Neu proteins could function as mediators of calcium signaling to the nucleus to regulate gene expression. There is evidence that in Drosophila and also in vertebrates, ligand activated Notch is subjected to proteolytic cleavage and transported to the nucleus where it acts as a transcriptional regulator (Jarriault et al 1995; Ohtsuka et al., 1999). Interestingly, recently it was shown that d-neu protein is associated primarily with the plasma membrane (Yeh et al., 2000). This, however, does not exclude the possibility that Neu1, like Notch, may be localized also within the nucleus. Based on current knowledge it is hypothesized that Neu1 functions as a mediator of an extracellular signal from the plasma membrane to the nucleus to regulate gene expression. According to one possible scenario, Neu1 is posttranslationally modified in a signal (Ca2+)-dependent fashion and subsequently translocated into the nucleus, where it functions as a transcriptional regulator.
- Neurogenic Function of Neu.
- Drosophila neuralized (d-neu) and h-neu1 genes encode homologous (˜40%) proteins with a C-terminal C3HC4 RING zinc finger domain (RZD) and one or two neuralized homology repeat (NHR) domains. Boulianne et al., EMBO J, 10:2975-2983 (1991) and Price et al., EMBO J, 12:2411-2418 (1993). d-neu is expressed in the ectoderm at the time when cell fate is determined, implying the role of Neu in neurogenesis. Boulianne et al., EMBO J, 10:2975-2983 (1991).
- In Drosophila, d-neu expression has been detected earliest in the ectoderm continuing later in neuroblasts. Boulianne et al., EMBO J. 10:2975-2983 (1991). Since developing mouse CNS can be divided into regions that express either high or low levels of neu1, and as neu1 is not expressed in proliferating regions of the nervous system, it suggests that other neu-related genes function in a fashion complementary to neu1. Indeed, based on the recent findings we could argue that neu1 defines a new gene and protein family consisting of at least two Drosophila and four mammalian genes.neu2, second member of mammalian neu family of genes, is expressed at high levels in the embryonic brain, whereas the expression levels decrease during postnatal development. Recent studies of the brain development in Drosophila and vertebrates, indicate that many basic molecular and genetic mechanisms involved in neurogenesis are highly conserved. Lewis, J. Curr Opin Neurobiol, 6:3-10 (1996); Kageyama et al., Int J Biochem Cell Biol, 29:1389-1399 (1997); and Beatus & Lendahl, J Neurosci Res, 54:125-136 (1998). For example, postnatal Notch signaling affects the elaboration of different body systems and regulates plasticity of cortical postmitotic neurons. Artavanis-Tsakonas et al., Science, 284:770-776 (1999); Redmond et al., Nat Neurosci, 3:30-40 (2000); and Sestan et al., Science, 741-746 (1999).
- Earlier genetic studies in Drosophila suggested that delta, mastermind, big brain, and neuralized refine a signal upstream of notch and that mastermind functions upstream of all the other neurogenic genes. Campos-Ortega and Jan, Annu Rev Neurosci, 14:399-420 (1991); and Lieber, Genes Dev, 7:1949-1965 (1993). Therefore, if the function of the mammalian Neu family of proteins is conserved in conjunction with other neurogenic factors, mammalian neu genes refine the signal upstream of mammalian homologues of notch and downstream of mastermind in tissues where neu genes are expressed, particularly in developing nervous system. Given that mammalian neu mRNAs encode different protein isoforms, complex regulatory circuits implicating various Neu family members are expected in different tissues. The transcription repression activities of mammalian Neu could well-explain its function as a neurogenic gene.
- Neu Role in Cell Signalling and Synaptogenesis
- Suppression of gene expression plays an important role in the maintenance and stability of a mature nervous system. It is essential to suppress neurite growth and extensive formation of new axons and dendrites in the adult functional nervous system and to maintain neurons in their differentiated state. Transcriptional repressors are involved and play a crucial role in the silencing of the neurite growth program.
- Mammalian neu1 shows most prominent expression in the postnatal central nervous system, revealing its function in postnatal development. neu1 mRNA expression levels increase significantly during the early postnatal development when active synaptogenesis takes place, to reach the peak levels in the adult animal. In the adult mammalian CNS, the highest expression levels of neu1 assign to the neurons of hippocampus, cerebral cortex, striatum, and amygdala. Whereas several brain regions such as thalamus/hypothalamus, midbrain, medulla, and also the spinal cord exhibit low expression. This indicates to the independent regulation of neu1 expression in various brain regions by specific signaling mechanisms as well as to the requirement of Neu function for different cell-cell signaling systems.
- neu1 mRNA expression studies in adult rat brain revealed that in several brain regions, particularly in the granular cells of dentate gyrus of hippocampus, neu1 mRNA is localized in the dendrites, suggesting that synthesis of Neu1 protein also occurs in dendrites. Several data indicate that proteins locally translated from dendritic mRNAs at activated synapses provide basis for activity-dependent regulation of synaptic modulation (reviewed in Steward et al., Neuron, 21:741-51 (1997); Kuhl and Skehel, Curr Opin Neurobiol, 8(5):600-6 (1998); Schuman, Neuron, 23:645-8 (1999); Tiedge et al., Science, 283:186-7 (1999); Kiebler and DesGroseillers, Neuron, 25:19-28 (2000)). Accordingly, Neu could be involved in the regulation of neuritogenesis and/or synaptogenesis, affecting the generation of the precise pattern of neuronal connectivity. Recent molecular perturbation experiments suggested that Notch1 signalling in cortical neurons promotes dendritic branching and inhibits neurite growth (Redmond et al., 2000; Sestan et al., 1999). Suggesting that the function of neu1 to refine a signal upstream of Notch in Drosophila is evolutionary conserved in mammalian nervous system, it is possible, that Neu and Notch pathways act in an interrelated manner to confer developmental plasticity to adult neurons. The possible similarities in the molecular mechanisms of function of two genes, Notch and neu1, that were first discovered as neurogenic, are appealingly apparent.
- Neu Role Related to Repair and Regeneration After Injury to the CNS
- A specific temporal order of events at the cellular and molecular level occurs in response to injury to the brain. Injury-compromised neurons degenerate while surviving neurons undergo neuritogenesis and synaptogenesis to establish neuronal connectivity destroyed in the injury. In the brain, after kainate-induced change in neuronal activity (a neurotoxic, excitotoxic or ischemic insult), it was observed that a consistent down-regulation of neu1 mRNA in the hippocampal formation with a strong reduction in the molecular layer where granule cell dendrites were present. It is suggested, that after injury of the CNS, down-regulation of neu1 mRNA expression leads to reduced levels of Neu1 protein that is essential for derepression of the transcription of its target genes related to repair and regeneration, such as growth factors and synaptic proteins.
- Neu Role in Memory and Learning
- Another function of the Neu family of transcription factors is mediation of Ca2+ signaling in a variety of neural processes including learning and memory. A member of Homer family of proteins, Homer2a, is referred to as an interactor of human Neu1 (GenBank Acc. No. AF081530). Homer proteins are enriched in excitatory synapses, bind group I metabotropic glutamate receptors (mGluR), and NMDA receptor interacting Shank proteins and thus can link NMDA and group I mGluR signaling pathways (reviewed in Xiao et al., Curr Opin Neurobiol, 10:370-74 (2000)). Given that Homer2a and Neu1 are co-expressed in various brain structures, it is highly conceivable that Neu1 participates in the regulation of glutamate receptor signalling in the adult brain. Glutamate receptor signaling has been implicated in several forms of activity-dependent synaptic plasticity, neurodegenerative diseases, cortical development and addiction. Consequently, if Neu is involved in glutamate receptor signaling, then the change in Neu structure, expression or function could lead to various developmental disorders and mental diseases.
- Thus, it is highly conceivable that neu1 mRNA expression is regulated by physiological neuronal synaptic activity leading to reduced levels of Neu1 protein and derepression of the transcription of its target genes in the processes involving memory and learning. This function of the Neu family transcription factors makes them a good target for a variety of drugs that control different processes in the brain, during development and in disease. Manipulating this function of Neu can be used to control a variety of diseases including depression, pain, anxiety, and neurodegenerative diseases.
- Neu Role in Tumorigenesis
- Also, this invention relates to the role of the Neu family of factors in the development of tumors, since the human neu1 gene has been mapped to
chromosome 10 within a region which is frequently deleted in gliomas. neu1 is expressed at varying levels in different neural and neuroendocrine tumors, including neuroblastomas, carcinoids, non-small cell lung cancers, and gliomas, suggesting that expression of Neu family of proteins is applicable as tumor-specific markers in clinical tumor diagnostics. Since over-expression of Neu1 blocks DNA synthesis in neuroblastoma and glioma cells, Neu family of proteins may function also as tumor suppressor genes. - Neu Role in Myogenesis and Development of Other Organ Systems.
- The described herein, especially in the Examples below, show that expression of neu1 and neu2 is found to be high in at late embryonic and adult stages of development, also in developing heart and testes. neu3 was found to be widely expressed, with highest levels in immune tissues spleen and thymus and in lung. Expression of neu4 was detected only in muscle and heart. Since Neu proteins are expressed at various levels in many different body systems, the role of Neu family of proteins in several developmental pathways is apparent. Studies of neumut flies have reported the overproduction of nautilus (nau) expressing cells in embryonic and muscle defects in adult stages of development. Corbin et al., Cell, 67:311-323 (1991); Hartenstein et al., Development, 116:1203-1220 (1992). nau is a myogenic bHLH factor that plays a role in the differentiation of muscle progenitors in Drosophila. Keller et al., Dev Biol, 181:197-212 (1997); Keller et al., Dev Biol, 202:157-171 (1998). Notch signaling has been shown to inhibit MyoD expression and block myogenesis in mouse. Kuroda et al., J Biol Chem, 274:7238-7244 (1999). It is possible that during mammalian myogenesis Neu refines Notch signaling by regulating expression of nau mammalian homologues (MyoD, myf5, myogenin and MRF4).
- Another function of the Neu family of transcription factors is mediation of Ca2+ signaling in muscle and other tissues. This function of the Neu family transcription factors makes them a good target for a variety of drugs that control different processes in the muscle, and in those tissues where Neu is expressed. Manipulating Neu expression and function can be used to control a variety of diseases including cancer, and muscle-degenerative diseases, dystrophinopathies, Brody's disease, and malignant hyperthermia (the last three are caused by the functional alterations of Ca(2+) signaling).
- Neu Interactions with Neurogenic Genes
- Additionally, activity of transcriptional regulators is modulated through interactions with other regulatory factors. Analyses of interactions between Drosophila neurogenic loci has revealed that neu appears to act upstream of notch (N), enhancer of split (E(spl)) and delta (Dl), and downstream of mastermind (mam). Boulianne et al., EMBO J. 10(10), 2975-2983 (1991). Interaction between neu and E(spl) is observed in the dominant mutation E(spl)Dl, which is a mutation that enhances the phenotype of split whereas split is a mutation in the N gene. Enhancement of the split phenotype increases in the presence of additional copies of neu gene, but decreases in heterozygotes for neu mutations. Molecular interactions between these Drosophila neurogenic genes are unknown. Expression of rat SHARP1 gene (Rossner, et al., Mol Cell Neurosci, 10(3-4):460-475 (1997)), one of the vertebrate homologues of Drosophila E(spl), is almost identical to the neu1 expression pattern during development and in adult tissues. The similarity in expression patterns between neu1 and SHARP1 suggests that products of these genes could reciprocally affect the function of the other as it occurs in Drosophila between neu and E(spl) genes.
- Neu Interactions with Proteins Implicated in Nuclear Transport
- The nucleocytoplasmic transport of functional molecules is mediated bidirectionally through the nuclear pore complex (NPC), which spans the double membranes of the nuclear envelope. It has recently been shown that signaling between the nucleus and the cytoplasm plays a key role in coordinating the cellular processes such as the cell cycle and cell differentiation (Yoneda, Cell Struct Funct 25:205-206. 2000). The weak NLS sequences (HKAVKR (SEQ ID NO: 43), RLKITKK (SEQ ID NO: 44)), that were identified in mammalian Neu1 proteins, are indeed, implicated in the regulated nuclear import of Neu1. Importin-α family members are involved in the formation of the NLS receptor complexes that govern the protein transport to the nucleus. Ullman et al., Cell, 90:967-970 (1997); and Izaurralde and Adam, RNA, 4:351-364 (1998). We have identified importin-α3 as one of the m-Neu interacting proteins by yeast two-hybrid screening.
- Neu Interactions with Miz1/GBP/PIAS Family of Proteins
- Yeast two hybrid screening revealed that Neu1 interacts with NeuI-1 which is a new splice variant of Miz1/PIASX zinc finger transcription factor. Miz1 is a sequence specific DNA binding protein that functions as a positive-acting transcription factor and interacts directly with homeobox transcription factor Msx2. Wu et al., 1997 Mech Dev, 65(1-2):3-17 (1997). Msx1 and Msx2, members of the Msx family of homeobox genes, were found to be important in inductive tissue interactions. Whereas Msx3 was expressed exclusively in the developing nervous system. Wang, et al., Mech Dev, 58(1-2):203-15 (1996). Members of the PIAS family, however, regulated DNA binding of STAT transcription factors thereby interfering with the signaling of a variety of cytokines. Chuang, et al., Biochem Biophys Res Commun, 18;235(2):317-20 (1997) and Liu et al., Proc Natl Acad Sci USA, 95(18):10626-31 (1998).
- Sequence analyses revealed that PIAS1 is identical to Gu/RNA helicase II (Gu/RH-II) binding protein GBP. Valdez et al., Biochem Biophys Res Commun, 234(2):335-40 (1997). The GBP regulates proteolytic cleavage of Gu/RH-II which could alter its functions or enzymatic activities or lead to its destruction. These data indicate that the Neu family of proteins could be involved, perhaps through its interactions with various proteins, such as the NeuI-1 protein. Such interactions may be involved in several biologically important regulatory processes including inductive tissue interactions (Miz1), cytokine signaling (PIAS), and RNA processing (GBP).
- Neu Interactions with ZNF127 Zinc Finger Family of Proteins
- Yeast two hybrid screening revealed that Neu1 interacts with NeuI-2. This protein is a new member of the ZNF127 zinc finger family of proteins. The ZNF127 gene is localized in Angelman/Prader-Willi region. Disruption of this gene causes a genetic defect related to mental retardation. ZNF127, as well as other genes in this region, were subjected to genomic imprinting (Mowery-Rushton et al., DNA methylation patterns in human tissues of uniparental origin using a zinc-finger gene (ZNF127) from the Angelman/Prader-Willi region Am J Med Genet, 61(2):140-6 (1996)). The role of ZNF127 in the development of Angelman/Prader-Willi syndrome, as well as its molecular function, is unknown. The ZNF127 family proteins, however, contain the zinc finger motif, Cx(8)Cx(5)Cx(3)-H, which is characteristic for viral and early immediate genes such as TIS11, ERF-2 (Tabara et al., 1999 pos-1 encodes a cytoplasmic zinc-finger protein essential for germline specification in C. elegans Development, 126(1):1-11); and also to RNA binding proteins (Carballo et al. Science, 281:1001-1005 (1998)).
- Neu Interactions with Parkin-Like Proteins
- The NeuI-3 protein is another interactor with Neu1 and was found to be similar to the recently described human gene parkin (Kitada, et al., Nature 392(6676):605-8 (1998). Mutations in the parkin gene have been shown to result in autosomal recessive juvenile parkinsonism. The molecular function of the parkin encoded protein is unknown. Phylogenetic analysis reveals that ari and parkin are distant members of a common progeny.
- Neu Interactions with Androgen Receptor Coregulator ARA54
- NeuI-4, another Neu interactor, is identical to ARA54, an androgen receptor coregulator (Kang et al., J. Biol. Chem. 274, 8570-8576; 1999). Furthermore, the RING-zinc finger domain of NeuI-4 has high similarity to Drosophila protein ariadne (ari) that could be involved in axonal path-finding. Aguilera, et al., Genetics 155(3):1231-44 (1996). Two mammalian homologues of ari have been identified, however, no information is available about molecular mechanisms of the functioning of the ari family of proteins.
- Neu Function Based on the Nature of Neu Interactors
- Based on the nature of Neu1 interactors, it is hypothesized that Neu has the potential to interfere with inductive tissue interactions (NeuI-1/Miz), cytokine signalling (NeuI-1/PIAS), RNA processing (NeuI-1/GBP), early immediate responses (NeuI-2/ZNF127), death of specific cell populations (NeuI-3/parkin), and nuclear hormone receptor signaling and axonal path-finding (NeuI-4/ariadne).
- Nucleic Acids
- Having identified a number of potential functions for the Neu family of proteins, the described invention seeks to utilize this knowledge to manipulate the various developmental pathways in which Neu functions. As a preliminary step, representative members of the Neu family of proteins have been isolated and purified. Polynucleotide molecules encoding the proteins of the Neu family were then isolated and their sequences are provided below.
- Representative polynucleotide molecules encoding members of the Neu family include sequences comprising SEQ. ID. NOs.: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33. Polynucleotide molecules encoding Neu family members include those sequences resulting in minor genetic polymorphisms, differences between species, and those that contain amino acid substitutions, additions, and/or deletions.
- In some instances, one can employ such changes in the sequence of a recombinant Neu to substantially decrease or even increase the biological activity of Neu relative to the wild-type Neu activity. Such changes can also be directed towards endogenous neu sequences using, for example, gene therapy methods to alter the gene product. Advantageously, the disclosed sequences can be used to identify and isolate neu polynucleotide encoding molecules from suitable vertebrate host cells. Thus, in another embodiment, a method of identifying neu polynucleotide molecules is provided.
- The nucleotide sequences encoding the neuralized homology repeat domain can be used to identify polynucleotide molecules encoding other proteins of the Neu family. Complementary DNA molecules encoding Neu family members can be obtained by constructing a cDNA library from mRNA of, for example, brain or muscle tissues that are at different developmental stages. DNA molecules encoding Neu family members can be isolated from such a library using the disclosed sequences in standard hybridization techniques or by amplification of sequences using polymerase chain reaction (PCR) amplification.
- In a similar manner, genomic DNA encoding Neu can be obtained using probes designed from the sequences disclosed herein. Suitable probes for use in identifying Neu family sequences can be obtained from Neu-specific sequences that are highly conserved regions between mammalian coding sequences. Primers, for example, from the neuralized
homology motif domains - neu family polynucleotide molecules can be isolated using standard hybridization techniques with probes of at least about 7 nucleotides in length and up to and including the full coding sequence. Other members of the neu family can be identified using degenerate oligonucleotides capable of hybridization based on the sequences disclosed herein for use PCR amplification or by hybridization at moderate or greater stringency. The term, “capable of hybridization” as used herein means that the subject nucleic acid molecules (whether DNA or RNA) anneal to an oligonucleotide of 15 or more contiguous nucleotides of SEQ. ID. NOs.: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33.
- The choice of hybridization conditions will be evident to one skilled in the art and will generally be guided by the purpose of the hybridization, the type of hybridization (DNA-DNA or DNA-RNA), and the level of desired relatedness between the sequences. Methods for hybridization are well established in the literature. One of ordinary skill in the art realizes that the stability of nucleic acid duplexes will decrease with an increased number and location of mismatched bases; thus, the stringency of hybridization can be used to maximize or minimize the stability of such duplexes. Hybridization stringency can be altered by: adjusting the temperature of hybridization; adjusting the percentage of helix-destabilizing agents, such as formamide, in the hybridization mix; and adjusting the temperature and salt concentration of the wash solutions. In general, the stringency of hybridization is adjusted during the post-hybridization washes by varying the salt concentration and/or the temperature, resulting in progressively higher stringency conditions.
- An example of progressively higher stringency conditions is as follows: 2×SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2×SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2×SSC/0.1% SDS at about 42° C. (moderate stringency conditions); and 0.1×SSC at about 68° C. (high stringency conditions). Washing can be carried out using only one of these conditions, e.g., high stringency conditions, or each of the conditions can be used, e.g., for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically. In general, conditions of high stringency are used for the hybridization of the probe of interest.
- Alternatively, polynucleotides having substantially the same nucleotide sequence set forth in SEQ. ID. NOs.: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33 or functional fragments thereof, or nucleotide sequences that are substantially identical to SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33, can represent members of the Neu family of proteins. By “substantially the same” or “substantially identical” is meant a nucleic acid or polypeptide exhibiting at least 80%, 85%, 90%, 95% or 100% homology to a reference nucleic acid. For nucleotide sequences, the length of comparison sequences will generally be at least 10 to 500 nucleotides in length. More specifically, the length of comparison will be at least 50 nucleotides, at least 60 nucleotides, at least 75 nucleotides, and at least 110 nucleotides in length.
- One embodiment of the invention provides isolated and purified polynucleotide molecules encoding Neu proteins, wherein the polynucleotide molecules that are capable of hybridizing under moderate to stringent conditions to an oligonucleotide of 15 or more contiguous nucleotides of SEQ. ID. NOs.: 1, 3, 5, 7,9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33, including complementary strands thereto.
- DNA sequences of the invention can be obtained by several methods. For example, the DNA can be isolated using hybridization or computer-based techniques which are well known in the art. Such techniques include, but are not limited to: 1) hybridization of genomic or cDNA libraries with probes to detect homologous nucleotide sequences; 2) antibody screening of expression libraries to detect cloned DNA fragments with shared structural features; 3) polymerase chain reaction (PCR) on genomic DNA or cDNA using primers capable of annealing to the DNA sequence of interest; 4) computer searches of sequence databases for similar sequences; and 5) differential screening of a subtracted DNA library.
- Screening procedures which rely on nucleic acid hybridization make it possible to isolate any gene sequence from any organism, provided the appropriate probe is available. Oligonucleotide probes, which correspond to a part of the neu family of sequences provided herein and encoding a Neu protein family member, can be synthesized chemically. This requires that short, oligo-peptide stretches of the amino acid sequence be known. The DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate. This includes a heterogeneous mixture of denatured double-stranded DNA. For such screening, hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA. Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present. In other words, by using stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete complement. (Wallace, et al., Nucl. Acid Res., 9:879, 1981). Alternatively, a subtractive library is useful for elimination of non-specific cDNA clones.
- Among the standard procedures for isolating cDNA sequences of interest is the formation of plasmid- or phage-carrying cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of gene expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned. In those cases where significant portions of the amino acid sequence of the polypeptide are known, the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA can be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single-stranded form (Jay, et al., Nucl. Acid Res., 11:2325, 1983).
- The nucleotide sequences of the present invention have a myriad of applications. Representative uses of the nucleotide sequences of the invention include the construction of cDNA and oligonucleotide probes useful in Northern, Southern, and dot-blot assays for identifying and quantifying the level of expression of Neu family proteins in a cell. Lack of expression of a Neu protein in tumors, diseased cells or tissues can indicate that measuring the level of Neu expression can provide prognostic markers for assessing the growth rate and invasiveness of a tumor.
- In addition, considering the important role of Neu in development and Ca2+ signaling, it is thought highly likely that birth defects, degenerative, and psychiatric diseases can result from expression of an abnormal Neu protein. In this case, the Neu protein family can prove highly useful in prenatal screening of mothers and/or for in utero testing of fetuses. Also, early diagnosis of degenerative and neurological diseases can be based on the analyses of changes in Neu expression and mutations in the neu genes.
- Similarly, the nucleotide sequences can be employed for the construction of recombinant cell lines, ova, and transgenic embryos and animals including dominant-negative and “knock-out” recombinant cell lines in which the regulatory activity of Neu protein is down-regulated or eliminated. Such cells can contain altered Neu coding sequences that result in the expression of a Neu protein that is not capable of enhancing, suppressing or activating transcription of the target gene. The subject cell lines and animals find use in screening for candidate therapeutic agents capable of either substituting for a function performed by Neu or correcting the cellular defect caused by a defective Neu.
- The Neu family of proteins presents an attractive set of diagnostic and therapeutic targets, considering the important regulatory role this family of proteins plays in the development function of adult organisms. This important role is reflected by the effects one or defects in a mutant Neu protein can inflict upon an organism. Moreover, with the advances in art of gene therapy progresses, these defects can be correctable in utero or in early post-natal life or alternatively through the use of compounds identified in screening assays using Neu proteins. In addition, neu polynucleotide molecules can be joined to reporter genes, such as beta-galactosidase, luciferase, or green fluorescent proteins (GFP) and inserted into the genome of a suitable host cell such as an embryonic or tissue specific stem cell by, for example, homologous recombination. Cells expressing neu can then be obtained by subjecting the differentiating cells to cell sorting, leading to the purification of a population of neu expressing cells. These cells can be useful for studying specific activity of isolated cell populations. Also, these cells can be used to study sensitivity to growth factors or chemotherapeutic agents.
- In yet another application of the nucleotide sequence discovery, the technology can be useful in the construction of gene transfer vectors (e.g., retroviral vectors, and the like). In these vectors, the neu sequence is often inserted into the coding region of the vector under the control of a promoter. neu gene therapy can be used to correct neurological and movement diseases and cancer. For these therapies, gene transfer vectors can either be injected directly at the site of diseased cells, or the vectors can be used to construct transformed host cells that are then injected at the site of disease.
- In one embodiment, a vector comprising a DNA molecule coding a Neu protein is provided. Preferably, a DNA molecule coding a Neu protein is inserted into a suitable expression vector, which is in turn used to transfect or transform a suitable host cell. Exemplary expression vectors for use in carrying out the present invention include a promoter capable of directing the transcription of a polynucleotide molecule of interest in a host cell. Representative expression vectors include both plasmid and/or viral vector sequences. Suitable vectors include retroviral vectors, vaccinia viral vectors, CMV viral vectors, BLUESCRIPT (Stratagene, San Diego, Calif.) vectors, baculovirus vectors, and the like. In another embodiment, promoters capable of directing the transcription of a cloned gene or cDNA can be inducible or constitutive promoters and include viral and cellular promoters. In particularly preferred embodiments, viral vectors are employed for use in expressing Neu proteins in mammalian cells particularly if neu is used for gene therapy.
- In some embodiments, it can be preferable to use a selectable marker to identify cells that contain the cloned DNA. Selectable markers are generally introduced into the cells along with the cloned DNA molecules and include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. Selectable markers can also complement auxotrophies in the host cell. Other selectable markers provide detectable signals, such as beta-galactbsidase to identify cells containing the cloned DNA molecules. Advantageously, the selectable markers are amplifiable. Such amplifiable selectable markers can be used to amplify the number of sequences integrated into the host genome.
- Antisense
- Antisense neu nucleotide sequences can be used to block expression of mutant neu expression in a variety of cell types. Suitable antisense oligonucleotides are at least 11 nucleotides in length and can include untranslated (upstream or intron) and associated coding sequences. As will be evident to one skilled in the art, the optimal length of an anti sense oligonucleotide depends on the strength of the interaction between the antisense oligonucleotide and the complementary mRNA, the temperature and ionic environment in which translation takes place, the base sequence of the antisense oligonucleotide, and the presence of secondary and tertiary structure in the mRNA and/or in the antisense oligonucleotide. Suitable target sequences for antisense oligonucleotides include intron-exon junctions (to prevent proper splicing), regions in which DNA/RNA hybrids will prevent transport of mRNA from the nucleus to the cytoplasm, initiation factor binding sites, ribosome binding sites, and sites that interfere with ribosome progression.
- Antisense oligonucleotides can be prepared, for example, by the insertion of a DNA molecule containing the target DNA sequence into a suitable expression vector such that the DNA molecule is inserted downstream of a promoter in a reverse orientation as compared to the gene itself. The expression vector can then be transduced, transformed or transfected into a suitable cell resulting in the expression of antisense oligonucleotides. Alternatively, antisense oligonucleotides can be synthesized using standard manual or automated synthesis techniques. Synthesized oligonucleotides are introduced into suitable cells by a variety of means including electroporation, calcium phosphate precipitation, or microinjection. The selection of a suitable antisense oligonucleotide administration method will be evident to one skilled in the art. With respect to synthesized oligonucleotides, the stability of antisense oligonucleotide-mRNA hybrids are advantageously increased by the addition of stabilizing agents to the oligonucleotide. Stabilizing agents include intercalating agents that are covalently attached to either or both ends of the oligonucleotide. In preferred embodiments, the oligonucleotides are made resistant to nucleases by, for example, modifications to the phosphodiester backbone by the introduction of phosphotriesters, phosphonates, phosphorothioates, phosphoroselenoates, phosphoramidates, phosphorodithioates, or morpholino rings.
- Protein Production
- As would be evident to one skilled in the art, the polynucleotide molecules of the present invention can be expressed in a variety of prokaryotic and eucaryotic organisms. For example, the Neu family of proteins can be expressed in to, Saccharomyces cerevisiae, filamentous fungi, and bacteria, such as E. coli to produce Neu proteins. Similarly, one can express the protein of the described invention in other host cells such as avian, insect, and plant cells using regulatory sequences, vectors, and methods well established in the literature.
- Neu proteins produced according to the present invention can be purified using a number of established methods such as affinity chromatography using anti-Neu antibodies coupled to a solid support. Fusion proteins of antigenic tag and Neu can be purified using antibodies to the tag. Optionally, additional purification is achieved using conventional purification means such as liquid chromatography, gradient centrifugation, and gel electrophoresis, among others. Methods of protein purification are known in the art and can be applied to the purification of recombinant Neu described herein.
- Amino Acids
- In one embodiment, the identification of mammalian Neu genes is provided. Preferably, the mammalian Neu genes have highly conserved sequences across the neuralized homology motif domains at the amino acid level (Neu1,
Neu 2, Neu3, and Neu 4). The following Neu polypeptides or proteins have been identified: human neural Neu1 protein of SEQ. ID. NO.:2, human muscle Neu1 protein SEQ. ID. NO.:4; human Neu1 alternatively spliced form (h-neu1ΔNHR1) of SEQ. ID. NO.: 6; mouse neural Neu1 protein of SEQ. ID. NO.: 8; mouse muscle Neu1 protein SEQ. ID. NO.: 10; mouse Neu1 alternatively spliced form (m-neu1ΔNHR2A) of SEQ. ID. NO.: 12; mouse Neu1 alternatively spliced form (m-neu1ΔNHR2B) of SEQ. ID. NO.: 14;rat Neu 1 protein SEQ. ID. NO.: 16; rat Neu1 alternatively spliced form (r-neu1ΔNHR2A) of SEQ. ID. NO.: 18; rat Neu1 alternatively spliced form (r-neu1ΔNHR2B) of SEQ. ID. NO.: 20; human Neu2 protein of SEQ. ID. NO.: 22; human Neu2 alternatively spliced form (h-neu2ΔNHR1) of SEQ. ID. NO.: 24; human Neu2 alternatively spliced form (h-neu2ΔNHR2) of SEQ. ID. NO.: 26;rat Neu 2 protein SEQ. ID. NO.: 28; human Neu3 protein of SEQ. ID. NO.: 30; mouse Neu3 protein of SEQ. ID. NO.: 32; and human Neu4 protein (partial) of SEQ. ID. NO.: 34. - The described invention encompasses Neu variants that, for example, are modified in a manner that results in Neu proteins capable of translocating into the nucleus but unable to repress transcription. Fragments of Neu proteins that are capable of transcriptional repression but are incapable of translocating into the nucleus are also encompassed by the present description. Proteins retrieved from naturally occurring materials and closely related, functionally similar proteins retrieved by antisera specific to Neu, and recombinantly expressed proteins encoded by genetic materials (DNA, RNA, cDNA) retrieved on the basis of their similarity to the unique regions in the neu family of genes, are also encompassed by the present description.
- According to the present description, polynucleotide molecules encoding Neu encompass those molecules that encode Neu proteins or peptides that share identity with the sequences shown in SEQ. ID. NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34. Such molecules preferably share greater than 30% identity at the amino acid level with the disclosed sequences in Neu. In preferred embodiments, the polynucleotide molecules can share greater identity at the amino acid level across highly conserved regions such as the neuralized homology repeat domains and the RING-zinc finger domains.
- It is contemplated that amino acid sequences substantially the same as the sequences set forth in SEQ. ID. NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34, are encompassed by the described invention. A preferred embodiment includes polypeptides having substantially the same sequence of amino acids as the amino acid sequence set forth in SEQ ID NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34, or functional fragments thereof, or amino acid sequences that are substantially identical to SEQ ID NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34. By “substantially the same” or “substantially identical” is meant a polypeptide exhibiting at least 80%, preferably 85%, more preferably 90%, and most preferably 95% homology to a reference amino acid sequence. For polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids.
- Homology is often measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, substitutions, and other modifications.
- The term “functional fragments” include those fragments of SEQ ID NOs.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34, or other Neu family members that retain the function or activity of a Neu transcriptional regulator. One of skill in the art can screen for the functionality of a fragment by using the examples provided herein, where full-length Neu transcriptional factors are described. It is also envisioned that fragments of various Neu proteins that inhibit or promote transcription can be identified in a similar manner. Neu transcriptional activity can also be assayed by standard transcription assays.
- By “substantially identical” is also meant an amino acid sequence which differs only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, etc.) or by one or more non-conservative substitutions, deletions, or insertions located at positions of the amino acid sequence which do not destroy the function of the protein assayed, (e.g., as described herein). Preferably, such a sequence is at least 85%, more preferably identical at the amino acid level to SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34.
- By a “substantially pure polypeptide” is meant a Neu protein that has been separated from components which naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally occurring organic molecules with which it is typically associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, Neu protein. A substantially pure Neu polypeptide can be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid encoding a Neu polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.
- A protein is substantially free of naturally associated components when it is separated from those contaminants that accompany it in its natural state. Thus, a protein that is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure polypeptides include those derived from eukaryotic organisms but synthesized in E. coli or other prokaryotes.
- As would be evident to one skilled in the art, the polynucleotide molecules of the present disclosure can be expressed in a variety of prokaryotic and eucaryotic cells using regulatory sequences, vectors, and methods well established in the literature.
- Neu proteins produced according to the present invention can be purified using a number of established methods such as affinity chromatography using anti-Neu antibodies coupled to a solid support. Fusion proteins of antigenic tag and Neu can be purified using antibodies to the tag. Optionally, additional purification is achieved using conventional purification means such as liquid chromatography, gradient centrifugation, and gel electrophoresis, among others. Methods of protein purification are known in the art and can be applied to the purification of recombinant Neu described herein.
- Construction of interspecies hybrid Neu proteins and hybrid Neu proteins containing one or more domains from another Neu family member are also contemplated. Such hybrid proteins facilitate structure-function analyses. Similarly, hybrid proteins allow for the alteration of Neu activity by increasing or decreasing the transcriptional regulation of target genes. Hybrid proteins of the present invention contain the replacement of one or more contiguous amino acids of the native Neu with the analogous amino acid(s) of Neu from another species or other protein of the Neu family. Such interspecies or interfamily hybrid proteins include hybrids having whole or partial domain replacements. Such hybrid proteins are obtained using recombinant DNA techniques well known by one of skill in the art. Briefly, DNA molecules encoding the hybrid Neu proteins of interest are prepared using generally available methods such as PCR mutagenesis, site-directed mutagenesis, and/or restriction digestion and ligation. The hybrid DNA is then inserted into expression vectors and introduced into suitable host cells.
- One embodiment of the present invention involves the isolation of proteins that interact with Neu proteins and regulate Neu protein function or are regulated by Neu. Neu proteins can be used in immunoprecipitation to isolate interacting factors or used for the screening of interactors using different methods of two hybrid screening. Isolated interactors of Neu can be used to modify Neu activity or Neu can be used to modify the activity of interactors. Two hybrid screening has resulted in the isolation of several types of interactors. Sequence analyses showed that all interactors are novel proteins and contain RING-zinc finger domain located in the C-terminus of the protein. NeuI-1 (4 clones) is a novel splice variant (SEQ. ID. NOS.: 35, 36) of zinc finger protein Miz1/PIASXα/ARIP3 (GenBank accession numbers NM—008602; AF077953; AF077954; AF044058). NeuI-2 (3 clones) is a fourth homolog (SEQ. ID. NOS.: 37, 38; GenBank accession number AF277171; AF302084) of zinc finger protein ZNF127 (GenBank accession numbers U19106; U19107). NeuI-3 (9 clones) has highest homology to a human hypothetical protein (GenBank accession number AK001459) and to a Drosophila hypothetical protein (AAF56052.2) produced from CG4813 gene of a genomic scaffold (GenBank accession number AE003740) (SEQ. ID. NOS.: 39, 40). NeuI-4 (12 clones) is the homolog of the androgen receptor coactivator ARA54 (SEQ. ID. NO.: 32; GenBank accession number AF060544) (SEQ. ID. NO.: 41, 42).
- In still another embodiment, synthetic peptides, recombinantly derived peptides, fusion proteins, chiral proteins (stereochemical isomers, racemates, enantiomers, and D-isomers) and the like are provided which include a portion of Neu or the entire protein. The subject peptides have an amino acid sequence encoded by a nucleic acid which hybridizes under stringent conditions with an oligonucleotide of 15 or more contiguous nucleotides of SEQ. ID. NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33. Representative amino acid sequences of the subject peptides are disclosed in SEQ. ID. NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34. The subject peptides find a variety of uses, including preparation of specific antibodies and preparation of antagonists of Neu activity.
- Antibodies
- As noted above, the described teachings provide antibodies that bind to Neu. The production of non-human antisera or monoclonal antibodies (e.g., murine, lagomorph, porcine, equine) is well known and can be accomplished by, for example, immunizing an animal with Neu protein or peptides. Additionally, catalytic antibodies to nuclear isoforms of the Neu family of proteins or Neu protein metabolic intermediates that are transported into and out of the nucleus can be generated. For the production of monoclonal antibodies, antibody producing cells are obtained from immunized animals, immortalized and screened, or screened first for the production of the antibody that binds to the Neu protein or peptides and then immortalized. It can be desirable to transfer the antigen binding regions (e.g., F(ab′)2 or hypervariable regions) of non-human antibodies into the framework of a human antibody by recombinant DNA techniques to produce a substantially human molecule.
- Following synthesis or expression and isolation or purification of a Neu protein or a portion thereof, the isolated or purified protein can be used to generate antibodies and tools for identifying agents that interact with the Neu protein and fragments of the Neu protein. Depending on the context, the term “antibodies” can encompass polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. Antibodies that recognize Neu proteins and fragments of Neu proteins have many uses including, but not limited to, biotechnological applications, therapeutic/prophylactic applications, and diagnostic applications.
- For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc. can be immunized by injection with Neu proteins or any portion, fragment or oligopeptide that retains immunogenic properties. Depending on the host species, various adjuvants can be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (Bacillus Calmette-Guerin) and Corynebacterium parvum are also potentially useful adjuvants.
- Peptides used to induce specific antibodies can have an amino acid sequence consisting of at least three amino acids, and preferably at least 10 to 15 amino acids. Preferably, short stretches of amino acids encoding fragments of Neu proteins are fused with those of another protein such as keyhole limpet hemocyanin such that an antibody is produced against the chimeric molecule. While antibodies capable of specifically recognizing Neu proteins can be generated by injecting synthetic 3-mer, 10-mer, and 15-mer peptides that correspond to a protein sequence of Neu proteins into mice, a more diverse set of antibodies can be generated by using recombinant Neu proteins, purified Neu proteins, or fragments of Neu proteins.
- To generate antibodies to Neu proteins and fragments of Neu proteins, a substantially pure Neu protein or a fragment of Neu protein is isolated from a transfected or transformed cell. The concentration of the polypeptide in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the polypeptide of interest can then be prepared as follows:
- Monoclonal antibodies to Neu proteins or a fragment of Neu proteins can be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Koehler and Milstein (Nature 256:495-497 (1975), the human B-cell hybridoma technique (Kosbor et al. Immunol Today 4:72 (1983); Cote et al Proc Natl Acad Sci 80:2026-2030 (1983), and the EBV-hybridoma technique Cole et al. Monoclonal Antibodies and Cancer Therapy, Alan R. Liss Inc, New York N.Y., pp 77-96 (1985). In addition, techniques developed for the production of “chimeric antibodies”, the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used. (Morrison et al. Proc Natl Acad Sci 81:6851-6855 (1984); Neuberger et al. Nature 312:604-608(1984); Takeda et al. Nature 314:452-454(1985). Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce Neu protein-specific single chain antibodies. Antibodies can also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al., Proc Natl Acad Sci 86: 3833-3837 (1989), and Winter G. and Milstein C; Nature 349:293-299 (1991).
- Antibody fragments that contain specific binding sites for Neu proteins can also be generated. For example, such fragments include, but are not limited to, the F(ab′)2 fragments that can be produced by pepsin digestion of the antibody molecule and the Fab fragments that can be generated by reducing the disulfide bridges of the F(ab′)2 fragments. Alternatively, Fab expression libraries can be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (Huse W. D. et al. Science 256:1275-1281 (1989)).
- By one approach, monoclonal antibodies to Neu proteins or fragments thereof are made as follows. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein or peptides derived therefrom over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused in the presence of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, E., Meth. Enzymol. 70:419 (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2.
- Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein or peptides derived therefrom described above, which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and can require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991 (1971).
- Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19 in: Handbook of Experimental Immunology D. Wier (ed) Blackwell (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μM). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980). Antibody preparations prepared according to either protocol are useful in quantitative immunoassays that determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively (e.g., in diagnostic embodiments that identify the presence of a Neu protein in biological samples). It is also contemplated that various methods of molecular modeling and rational drug design can be applied to identify additional Neu protein family members, compounds that resemble a Neu protein or fragment or derivative thereof, and molecules that interact with Neu proteins and, thereby modulate their function.
- Additional Applications
- The Neu family of proteins presents an attractive set of diagnostic and therapeutic targets, considering the important regulatory role this family of proteins plays in the development function of adult organisms. This important role is reflected by the effects one or more defects in a mutant Neu protein can inflict upon an organism. Moreover, with the advances in the art of gene therapy, these defects can be corrected in utero or in early post-natal life or alternatively through the use of compounds identified in screening assays using Neu proteins.
- In some instances, cancer cells, or diseased cells or tissue, can contain a non-functional Neu protein or can contain no Neu protein due to a genetic mutation or somatic mutations such that these cells fail to stop proliferating and differentiate. For cancers of this type, the cancer cells can be treated in a manner to cause the over-expression of wild-type Neu protein to force differentiation and cease proliferation of the cancer cells. Accordingly, a method of treating cancer is similarly provided.
- It is also contemplated that because neu family genes control cell proliferation and Ca2+ signaling induced transcriptional processes, that manipulating Neu expression and function may be useful in controlling a variety of diseases, a few examples of which include depression, pain, anxiety, neurodegenerative diseases, and cancer.
- The practice of the described invention is illustrated in the following non-limiting examples. The examples are provided below are not intended to limit the invention in any way.
- A mouse cDNA library of postnatal day (P) 1 brain (Stratagene, San Diego, Calif.) was screened with a mouse 0.7 kb EST (GenBank #AA5 18339) cDNA clone corresponding to a region ranging from about the translation initiation codon to the end of the first neuralized homology repeat domain (NHR1) of h-neu1 (Nakamura et al., 1998).
- Sequence analyses, the results of which are shown in
FIG. 1 , revealed that the isolated cDNA clones differed in their 5′ regions encoding muscle- and brain-specific m-Neu1 proteins with different N-termini (FIG. 1 ). In the figure, “A” shows an amino acid sequence comparison of Drosophila, human, rat and mouse neu1 proteins. Various domain regions of the proteins are illustrated. The regions Brain-N, relating to the neural-specific N-terminal region, and Muscle-N, the muscle-specific N-terminal of mammalian neu proteins, are boxed. The NHR1 and NHR2 regions, neuralizedhomology repeat domains - RT-PCR analyses of RNA from mouse and rat brain and skeletal muscle resulted in identification of 6 different Neu1 transcripts in both species (
FIG. 1 ): 1) brain- and muscle-specific transcripts encoding Neu1 with the intact NHR2 domain (574 and 557 amino acids, respectively); 2) brain- and muscle-specific transcripts encoding Neu1 protein isoforms that lack the region between NHR1 and NHR2, the entire NHR2 region and different parts of the linker region preceding the RZD (Neu1-ΔNHR2A, 342 and 325 amino acids and Neu1-ΔNHR2B, 291 and 274 amino acids). - Turning again to
FIG. 1 , the region between asterisks is absent in the splice isoform neu1-ΔNHR2A; the region between the open circles is absent in the splice isoform neu1-ΔNHR2B; the pKB consensus sequence between NHR1 and NHR2; LRS, two putative leucine rich sequences in the end of both the NHR; and SP, the serine and proline rich repeats between the NHR2 and RZD are boxed. “B” is a schematic representation of the domain structure of different mouse and rat Neu1 isoforms. Structures of the full length Neu1 protein (neu, 574 amino acids) and of two Neu1 isoforms (neu-ΔNHR2A, 342 amino acids, neu-ΔNHR2B, 291 amino acids) are shown. Lines indicate to the alternative splicing resulting in the cDNAs encoding neu-ΔNHR2A and neu-ΔNHR2B isoforms. The numbers below the neu-ΔNHR2A and neu-ΔNHR2B correspond to the amino acids of the full length Neu1 protein. - Sequence analyses revealed that alternative splicing in the NHR2 and RZD linker region occurs in-frame and does not affect the intactness of the RING zinc finger structure. Accordingly, both m-neu1 and r-neu1 genes encode protein isoforms with one or two NHRs followed by the C3HC4-type RZD in the C-terminus. To date no proteins other than Neu1 proteins have been identified that contain NHR-like domains and the function of the NHR-like domains has not been previously identified. The RING zinc finger motifs are present in many regulatory proteins and have been shown to mediate protein-protein interactions. Saurin et al., Trends Biochem Sci, 21:208-214 (1996).
- Like h-Neu, m-Neu1 and r-Neu do not have sequences that are similar to the Lys-rich nuclear localization signal (NLS) in d-Neu. However, two smaller clusters of Arg and Lys rich amino acids (HKAVKAR (SEQ ID NO: 43) at 80-85 and RLKITKK (SEQ ID NO: 44) at 107-113) are present in the NHR1 of mouse, rat, and human Neu1 that resemble the phosphorylation consensus sequence of NLS, m-Neu1, r-Neu, and h-Neu proteins, which are rich in Ser and Thr residues. The presence of these regions suggests that Neu1 is regulated by phosphorylation. The region between NHR1 and NHR2 contains also a putative protein kinase B/AKT phosphorylation site RPRSFT (SEQ ID NO: 45) which is similar to the respective consensus sequence RXRXXS/T (SEQ ID NO: 46). Datta, et al., Genes and Dev, 13:2905-27 (1999).
- The region between NHR2 and RZD of m-Neu1, r-Neu, and h-Neu contains two imperfect repeats of Pro, Ser, and Thr residues with the consensus sequence S/TXPXSPXSXPXSPXXXGXXX(X)SD (SEQ ID NO: 47) where X denotes any amino acid. It is interesting to note that this SP repeat of mammalian Neu1 proteins is not similar to any known protein motifs.
- An RNase protection analyses (RPA) was used to determine the levels of m-neu1 and r-neu1 mRNAs in the developing and adult brain and non-neural tissues (
FIG. 2 ). - Total RNA was isolated from the mouse and rat brain regions, which are indicated (A) and (B) respectively in
FIG. 2 , and non-neural tissues. Levels of neu1 transcripts were analyzed by RNase protection assays. The cRNA probes used for detection of m-neu1 transcripts were complementary to a region encoding the muscle-specific (FIG. 2 , left panel) or the brain-specific (FIG. 2 , right panel) N-terminus and first half NHR1 of m-neu1. For r-neu1, the cRNA probe was complementary to a region encoding the second half of NHR2 up to the stop codon. Specific protected fragments are indicated on the right of each panel. - Bottom panels of
FIG. 2 show the levels of GAPDH mRNA in the RNA samples. The nomenclature used to identify each sample is as follows: neu-M, indicates a muscle-specific m-neu1 transcript; neuB, indicates a brain-specific m-neu1 transcript; neu-B/M indicates the total pool of muscle- and brain-specific r-neu1 transcripts. Further, E, denotes “Embryonic day”; P, denotes “postnatal day”; ad, denotes “adult”; th, denotes “thymus”; he, denotes “heart”; lu, denotes “lung”; sp, denotes “spleen”; ki, denotes “kidney”; li, denotes “liver”; mu, denotes “skeletal muscle”; gu, denotes “gut”; plac, denotes “placenta”; ctx, denotes “cerebral cortex”; cbl, denotes “cerebellum”; hc, denotes “hippocampus”; str, denotes “striatum”; mid, denotes “ventral midbrain”; hth, denotes “hypothalamus”; col, denotes “colliculi”; thal, denotes “thalamus”; pons, denotes “pons”; olf; denotes “olfactory bulb”; med, denotes “medulla”; pit, denotes “pituitary”; and tRNA, denotes “yeast tRNA”, which was used as a negative control. - The overall highest expression levels of neu1 mRNA were seen in the adult skeletal muscle and brain. In the skeletal muscle, neu1 mRNA levels were undetectable during embryonic development, low at birth and upregulated during postnatal development reaching the highest levels in the adult. Other non-neural tissues (heart, kidney, liver, lung, thymus, and spleen) except for the adult heart and testis did not express neu1 transcripts or the levels were below the detection limit of the RPA. In the brain, low levels of neu1 mRNA were detected at embryonic day (E) 13 and the expression increased progressively reaching the highest levels in the adult. neu1 expression levels were high in the cerebral cortex, hippocampus, and striatum and substantially lower in the olfactory system, thalamus/hypothalamus, midbrain, cerebellum, pons, and medulla.
- neu1 expression levels were specifically analyzed during postnatal development of cerebral cortex and cerebellum. In both of these brain regions, low levels of neu1 mRNA were observed in postnatal day (P) 1 whereas by two weeks after birth the expression levels increased significantly reaching the peak levels in the adult animal. High levels of neu1 mRNA expression were also detected in the adult dorsal root ganglia and moderate levels in the adult spinal cord. In all the tissues predominant neu1 transcripts contained intact NHR2 domain, whereas the levels the neu1 mRNAs lacking the NHR2 (neu1-ΔNHR1A and neu1-ΔNHR1B) were below 5% of all m-neu1 transcripts. Presented data show that neu1 is highly expressed during mouse and rat postnatal development and that the expression is confined to skeletal muscle and the nervous system.
- In situ hybridization analysis was used to study the cellular localization of neu1 mRNA expression in the embryonic and adult mouse brain. The results are presented in
FIG. 3 . - Shown are dark-field emulsion autoradiographs obtained after hybridization of coronal sections of mouse brain with the [35S]-labeled m-neu1 cRNA probe corresponding to the first neuralized homology region (NHR1) of neu1. m-neu1 mRNA-specific labeling is shown at embryonic day 17 (E17, upper panel), at postnatal day 7 (P7, middle panel) and adult (AD, lower panel) in different brain structures. Exposure time was 3 weeks for adult and P7 sections and 6 weeks for E17 sections. As shown in the figure, BG, denotes “basal ganglia”; Cx, denotes “cerebral cortex”; Th, denotes “thalamus”; PTec, denotes “pretectum”; SC, denotes “superior colliculi”; IC, denotes “inferior colliculi”; Cb, denotes “cerebellum”; Me, denotes “medulla”; Pit, denotes “pituitary”; P, denotes “pons”; Hc, denotes “hippocampus”; Am, denotes “amygdala”; and Pn, denotes “Pontine nuclei”.
- Results of these analyses supported the conclusions drawn from the RPA studies discussed in Example 2. Neuralized1 mRNA-specific labeling was not detected at E13 and E15 brain, because of very low expression levels. This result was supported by the related data produced from the RPA. At E17, all brain regions, except for the cerebral cortex, hippocampus, and cerebellum, were found to express low levels of m-neu1 mRNA. In the brain, m-neu1 expression was confined to the regions containing postmitotic neurons and was not present in ventricular and subventricular zones that contain proliferating neural stem and progenitor cells.
- At P7, the levels of neu1 mRNA increased significantly in the basal ganglia, amygdala, hypothalamus, and hippocampus. Low levels were present in the cerebral cortex and brainstem. In the adult, widespread expression of m-neu1 mRNA was observed throughout the brain particularly in the cerebral cortex, hippocampal formation, the basal ganglia, amygdaloid, hypothalamus, and pontine nuclei and in the cerebellum, while lower levels were seen in the mesencephalon and medulla oblangata. m-neu1 mRNA-specific signal was not detected in most of the thalamic nuclei.
- A more detailed analysis of neu1 expression was carried out in rat brain and the data is shown in Table 2 and in
FIGS. 4, 5 , and 6. -
FIG. 4 shows the results of an in situ hybridization analysis of neu1 mRNA expression in adult rat brain. The coronal sections (A-H) correspond to the levels from 5 Bregma in the atlas of Paxinos and Watson (Paxinus and Watson, 1986) as indicated by numbers in the left part of the bottom of each autoradiograph. CTX, denotes “cerebral cortex”; CPu, denotes “caudate putamen”; Pir, denotes “piriform cortex”; LS, denotes “lateral septum”; HDB, denotes “nucleus of the horizontal limb of the diagonal band of Broca”; VDB, denotes “nucleus of the vertical limb of the diagonal band of Broca”; GP, denotes “globus pallidus”, BSTM and BSTL, denotes “bed nucleus of the stria terminalis, medial and lateral division respectively”; MHb, denotes “medial habenular nucleus”; Rt, denotes “reticular thalamic nucleus”; AH, denotes “anterior hypothalamic area”; Zi, denotes “zona incerta”; Am, denotes “amygdaloid nuclei”; VMH, denotes “ventromedial hypothalamic nucleus”; DMD, denotes “dorsomedial hypothalamic nucleus”; DG, denotes “dentate gyrus”; CA1 and CA3, denotes “pyramidal layers of the hippocampus”; Ent, denotes “entorhinal cortex”; PAG, denotes “periaqueductal gray”; Sc, denotes “superior colliculus”; S, denotes “subiculum”; Pn, denotes “pontine nuclei”; GL, denotes “granular layer of cerebellum”; PL, denotes “Purkinje cell layer of cerebellum”; ECu, denotes “external cuneate nucleus”; Ve, denotes “vestibular nuclei”; Gi, denotes “gigantocellular reticular nucleus”; Sp5, denotes “spinal trigeminal nucleus”: PCRt and IRt, denote “parvicellular reticular nuclei” and “intermedial reticular nuclei”, respectively; LPGi, denotes “lateral paragigantocellular nucleus”; LRt, denotes “lateral reticular nucleus”; and Sol, denotes “solitary nucleus”. The scale bar corresponds to 5 mm in length. -
FIG. 5 shows expression of neu1 mRNA in an adult rat nervous system. Dark-field in situ hybridization autoradiographs showing labelling in A, the cerebral cortex; B, CA1-CA3, hippocampal subfields, and in the dentate gyrus (DG) including the strata molecular (Mol), lacunosum molecular (Lmol) and radiatum (Rad); C, substantia nigra compact part (SNc) and reticular part (SNr); D, medial habenular nucleus (MHb); E, locus coeruleus (LC); F, in the molecular (Mol) and granular (Gr) layer of cerebellar cortex; G, in the layers of the retina: ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), pigmental epitelial (PE); H, dorsal root ganglia (DRG). Roman numbers in A indicate the various layers of cerebral cortex; CC, corpus callosum; Hil, hilus; WM, white matter. The scale bars correspond lengths of 200 μm in A and 400 μm in B-H. -
FIG. 6 shows cellular localization of neu1 mRNA in an adult rat nervous system. Bright-field in situ hybridization microphotographs showing labelled cells in A, in the layer II of the cerebral cortex at the level of the somatosensory cortex (CTX); B, dentate gyrus (DG) of hippocampus; C, CA3 layer of the hippocampus; D, polymorph layer of dentate gyrus (PoDG); E, lateral septum (LS); F, substantia nigra compact part (SNc); G, globus pallidus (GP); H and I, spinal cord at L3 level, respectively in the layers 9 and 2-3 (Sc); J, dorsal root ganglia (DRG); K, glia limitans (GL); L, pineal gland (Pi). Note in G, the cells in the globus pallidus (GP) do not express neu1 mRNA. Mol, stratum moleculare; Hil, hilus of the hippocampus; Rad, stratum radiatum; Or, stratum oriens. The scale bar corresponds to 25 μm in length. - Overall, although the neu1-specific labeling was distributed broadly throughout the brain, more predominant expression was confined to forebrain structures and the levels were lower in caudal regions of the brain, with the exception of some nuclei (Table 2). In the olfactory system the anterior olfactory nucleus showed neu1-specific signal. In the cerebral cortex neu1 mRNA expression levels were particularly high (
FIG. 4A -F, 5A, 6A). In the cerebral cortex, highest levels of neu1 mRNA expression were found in layer I-III, whereas expression gradually decreases from layer IV to layer VI. Dense labeling was seen in layers I-III, and in scattered neurons of layer V, moderate levels in layers V and VI, and low levels in layer IV. (FIG. 5A, 6A ) Interestingly, labeling in layer I did not cover diffuse cell bodies, suggesting dendritic localization of neu1 mRNA. Piriform and entorhinal corticies were also labeled with neu1-specific signal. - In the hippocampus, neurons of the granular layer of dentate gyrus and the pyramidal layers CA1-CA3 showed moderate-high labeling (
FIG. 4C -E, 5B, 6B-D). Neurons of the hilus and subiculum expressed low levels of neu1 mRNA. The most interesting observation regarding neu1 mRNA localization in the adult brain was the clear dendritic localization of the transcripts in the hippocampus. The neu1-specific labeling over the molecular layer of the dentate granule cells was uniformly distributed (FIG. 4C -E). Examination of emulsion-dipped sections showed that this labeling did not cover cell bodies and extended up to the hippocampal fissure, showing that neu1 mRNA is localized throughout the entire dendritic tree of dentate granule cell layer (FIG. 5B, 6B ). The strata oriens and radiatum of CA1-CA3 of hippocampus, corresponding to the dendrites of these regions, were also labeled by neu1 cRNA but the levels were significantly lower than in the molecular layer of the dentate gyrus (FIG. 4C -E, 5B, 6C). - In the basal ganglia, r-neu1 cRNA was detected in caudate putamen and accumbens but not in the globus pallidus (
FIG. 4A , B, 6G). Moderate to high levels of neu1 mRNA were seen in all the amygdaloid nuclei (FIG. 4C -D), the interstitial nucleus of the posterior limb of anterior commissure and the bed of stria terminalis of extended amygdala (FIG. 4B ). In the septum, high levels of labeling were seen in the cells of lateral septum (FIG. 4A ; 6E), and very low levels in the vertical and horizontal limb of the diagonal band of Broca. In the hypothalamus, the supraoptic, suprachiasmatic, supramammilary, and ventromedial nuclei expressed moderate levels, and several other nuclei expressed low levels of neu1 mRNA (FIG. 4B -E). In the thalamus, the medial habenula expressed high levels of neu1 mRNA, while moderate levels were observed in the reticular thalamic nucleus and low levels in a few other nuclei of the thalamus, such as the zona incerta, lateral habenula, mediodorsal thalamic nuclei, laterodorsal thalamic nuclei, paraventricular thalamic nucleus, rheuniens, rhomboid thalamic nuclei, and medial pretectal nucleus (Table 1,FIG. 4C -D, 5D). In the mesencephalon, the neurons of the substantia nigra, colliculi superior, ventral tegmental area, periaqueductal gray, interpeduncular nucleus, oculomotor nucleus, and Raphe nucleus showed low levels of neu1-specific signal (FIG. 4F, 5C , 6F). The granule cell layer of the cerebellum was strongly labeled, but the Purkinje cells and deep cerebellar nuclei were not (FIG. 4G , H, 5F). Within myelenchepalon, the locus coeruleus, and the pontine, trapezoid body, facialis, pontine reticular, and rostroventrolateral reticular nuclei were labeled with moderate density with r-neu1 cRNA (Table 1,FIG. 4F, 5E ). Beyond this, there was low-density labeling in the trigeminal, facial, solitary, and hypoglossal nuclei (FIG. 4G , H). In addition, neu1 cRNA labeling was evident at low levels or in association with fewer cells in several other nuclei, such as the vestibular, cochlear, paragigantocellular, and abducens nuclei (Table 1). - In the retina, labeling of neu1 mRNA was strong in the inner nuclear layer, with the highest intensity in the outer border. Diffuse labeling was also seen in the ganglion cell layer and both in the inner and outer plexiform layers (
FIG. 5G ). Cells in the pineal gland expressed high levels of neu1 mRNA (FIG. 6L ). Finally, labeling was relatively low in the cells of the spinal cord (FIG. 6H , I), in contrast to the neurons of dorsal root ganglia, which expressed high levels of neu1 mRNA (FIG. 5H, 6J ). - At the cellular level, m-neu1 mRNA expression was predominant in cells displaying neuronal profile (large cells with weakly stained nuclei) and not in the cells with glial profile (small cells with strongly stained nuclei). In addition, neu1 mRNA expression was not detected in the white matter, where neuronal cells are absent. One of the few exceptions of non-neuronal neu1 mRNA expression was glia limitans that displayed dense labeling (
FIG. 6K ). - Using in situ hybridization in combination with immunocytochemistry for NeuN, a Neuron-specific protein, we found that clusters of silver grains, reflecting the presence of neu1 mRNA, were located over the perikarya of NeuN-positive cells in all the brain regions examined, such as cerebral cortex, hippocampal formation, striatum, hypothalamus nuclei, amygdaloid complex, and cerebellum.
FIG. 7 shows the results of neuronal expression studies of neu1 mRNA levels in adult rat brain In the figure, neu1 mRNA was visualized as autoradiographic grains whereas NeuN was shown as peroxidase staining resulting in a yellow color. The two labelings co-localized with all the cells. As shown in the figure: A, layer II of cerebral cortex (CTX); B, CA1 layer of the hippocampus; C, polymorph layer of the dentate gyrus (PoDG) and CA3 layer of the hippocampus; D, caudate putamen (CPu); E, reticular thalamic nucleus (Rt); and F, ventromedial hypothalamic nucleus (VMH), were studied Note that neurons (NeuN-positive cells) of the ventral posterolateral thalamic nucleus (VPL) in E do not express neu1 mRNA. - By evaluation the proportion of cells positive for both neu1 mRNA and NeuN out of the total number of NeuN-containing neurons, it was found that all the neurons in the layers II and III of the cerebral cortex expressed neu1 mRNA. In the layer IV eighty percent and layers V-VI about ninety percent of neurons expressed neu1 mRNA. In several other brain regions examined, such as hippocampal formation, striatum, reticular thalamic nucleus, hypothalamic nuclei, showing that the majority of the neuronal cells express neu1 mRNA. In contrast, neurons in the globus pallidus and in several thalamic nuclei, such as ventral posterolateral and posteromedial nuclei, did not express neu1 mRNA (
FIG. 7 ). - Neuronal activity has been shown to regulate the dendritic localization of the immediate-early gene arc mRNA. Steward et al., Neuron, 21:741-51 (1998); Guzovsky et al., Nat Neurosci, 2:1120-1124 (1999). To examine if neu1 mRNA dendritic localization is regulated by neuronal activity, the effect of kainate-induced seizures on the expression and localization of neu1 mRNA was studied (
FIG. 8 ). At 24 hours after the injection of kainate, neu1 mRNA levels decreased in all the regions of the hippocampus. The levels of neu1 mRNA are significantly downregulated in the granular and molecular layers of dentate gyrus of adult rat brain at 24 hours after the treatment with kainic acid (B and B1), as compared to control brains (A and A1). Regions analyzed are denoted as follows: CTX, cerebral cortex; DG, dentate gyrus; Am, amygdala; Pir, piriform cortex; VMH, ventromedial hypothalamic nucleus; and Mol, for the molecular layer of the hippocampus. Particularly pronounced was the reduction of labeling in the molecular layer of the dentate gyrus. Similarly, but less consistently, a down-regulation of neu1 mRNA was observed in the cerebral cortex. - The ability of m-Neu1 to act as a transcriptional regulator was studied using a chloramphenicol acetyl-transferase (CAT) assay. Several transcriptional regulators, such as the polycomb group-related transcriptional regulator MEL18, the MDM2 proto-oncogene, breast and ovarian cancer susceptibility gene BRCA1 and MAT1, a subunit of TFIIH basal complex factor contain RING finger motifs. Kanno et al., EMBO J, 14:5672-5678 (1995); Leveillard and Wasylyk, J Biol Chem, 272:30651-30661 (1997); Pao et al., Proc Natl Acad Sci USA, 97:1020-1025 (2000); and Fesquet et al., Oncogene, 15:1303-1307 (1997). Furthermore, the earlier studies proposed d-Neu to function as a DNA-binding transcription factor. Boulianne et al., EMBO J, 10:2975-2983 (1991) and Price et al., EMBO J, 12:2411-2418 (1993).
- The effect of m-Neu1 on transcriptional activity was studied using a chloramphenicol acetyl-transferase (CAT) assay and the following promoters: 1) TATA-box containing: 1.0 kb BDNF-I-CAT, 0.3 kb BDNF-II-CAT, 0,7 kb BDNF-IV CAT, 0.4 kb NF-L, 1.0 kb GAP-43, 2) TATA-less promoters with putative initiators (Inr): 0.4 kb BDNF-III-CAT, 0.4 kb LNGFR-CAT, and 0.3 kb ME1-CAT. Timmusk et al., Neuron, 10:475-489 (1993); Reeben et al., J Neurosci Res, 40:177-188 (1995); Chiaramello et al., J Biol Chem, 271:22035-22043 (1996); Metsis et al., Gene, 121:247-254 (1992); and Shain et al., Nucleic Acids Res, 23:1696-1703 (1995). Data from the study is shown in
FIG. 9 . -
FIG. 9 show that Neu1 represses transcription from various promoters in transient expression assays. The data for this figure was gathered from Neuro2A cells that were co-transfected with 0.5 μg of various reporter plasmids containing different promoters driving the epression of CAT and pRcCMV expression plasmid (1.0 μg) without any cDNA sequence (control) or containing m-neu1 cDNAs encoding the full length protein (neu-FL) or the m-Neu-1-ΔNHR2A (neuΔNHR2A) isoform lacking the region between NHR1 and RZD, using FuGENE-6 transfection system. The pON260 expression plasmid (0.1 μg) encoding β-galactosidase was included in the transfections to normalize the transfection efficiencies. The CAT activity is defined as 100 for each reporter when cotransfected with the pRcCMV parental expression plasmid. When cotransfected with expression plasmids containing m-neu1 cDNAs, the CAT activities are expressed relative to the value obtained by cotransfection of each reporter plasmid and the parental pRcCMV expression plasmid. The data shown are representative of at least three independent experiments. Error bars represent the S.E. BDNF-I, 1.0 kb BDNF promoter I, BDNF II, 0.3 kb BDNF promoter II; BDNF III, 0.4 kb BDNF promoter III; BDNF IV, 0.7 kb BDNF promoter IV; NF-L, 0.4 kb NF-L promoter; GAP-43, 1.0 kb GAP-43-promoter, LNGFR, 0.4 kb LNGFR promoter; ME1, 0.3 kb ME1 promoter. - The full-length and the isoform of m-Neu1-ΔNHR2A significantly reduced the activity of all of these promoters in Neuro-2A cells (
FIG. 9 ). CAT assays performed in other cell types (mouse teratocarcinoma PCC7, rat astrocytoma C6, human breast ductal carcinoma BT-549, human primary osteogenic sarcoma Saos2, human cervix carcinoma C-33A) or using a different reporter (RARβ promoter driven lac Z) gave similar results (data not shown), suggesting that the transcriptional repressor activity of m-Neu1 does not depend on the reporter and cellular context. - Following the identification of m-Neu1's activity as a transcriptional regulator, identification of the repression domains of m-Neu1 was performed. Expression plasmids were generated encoding full-length m-Neu1 or individual domains of m-Neu1 fused to Gal4 DNA-binding domain and tested their activities by CAT assays. The data is presented in
FIG. 10 . -
FIG. 10 shows that neuralized homology repeat domains of Neu1 mediate the transcriptional repression when fused to the DNA binding domain of Gal4. Neuro2A cells were cotransfected with Gal4TK-CAT reporter plasmid containing five Gal4 binding sites in front of TK promoter driving the expression of CAT (0.5 μg) and pBIND expression plasmid (1.0 μg) without any cDNA sequence (G4) or containing different regions of m-neu1 cDNA fused in-frame to Gal4 DNA-binding domain using FuGENE-6 transfection system. The designations of the constructs are shown on the left ofFIG. 10 . The CAT activities are expressed relative to the value obtained by cotransfection of the reporter plasmid and the parental pRcCMV expression plasmid which was set 100. The data shown are representative of at least three independent experiments. Error bars represent the S.E. - The co-transfection of full-length m-Neu1 fused to Gal4 (Gal4-m-Neu1) with the Gal4-TK-CAT resulted in a concentration-dependent repression of the CAT activity (
FIG. 10 ). m-Neu1 isoforms that lack the NHR2 and the region preceding the RZD also displayed transcriptional repressor activities when fused to Gal4 DBD (FIG. 10 ). Extensive deletion analyses showed that NHR1 and NHR2 domains possess transcriptional repressor activity, whereas neural and muscle-specific N-termini (amino acids 1-60), RZD (amino acids 509-574) and the serine-proline rich linker region joining RZD to NHR2 (amino acids 439-510) did not affect transcription (FIG. 10 ). Interestingly, individual NHR1 and NHR2 displayed even stronger repressor activities than the full-length m-Neu1. These data show that m-Neu1 acts as a transcriptional repressor when tethered to a promoter via a heterologous DNA binding domain (DBD). To summarize, m-Neu1 represses the activity of both TATA and TATA-less promoters in transient expression assays. - The function of Neu1 as a transcriptional repressor implies its nuclear localization. A putative lysine rich nuclear localization signal (NLS) that is present in d-Neu protein (d-NLS) is not conserved in mammals. Boulianne et al., EMBO J, 10:2975-2983 (1991) and Price et al., EMBO J, 12:2411-2418 (1993). To study the subcellular localization of m-Neu1 protein expression constructs were generated encoding tagged m-Neu-fusion proteins. The expression of these vectors was analyzed in Neuro2A cells.
- The results from this work is shown in
FIG. 11 . This figure shows the subcellular localization of m-Neu1-FLAG and m-Neu1-EGFP fusion proteins in Neuro2A cells. Neuro2A cells were transfected expression plasmids encoding m-Neu1-FLAG (A, E, F) and different m-Neu1-EGFP (B, C, D) fusion proteins or with parental pFLAG (G) and pEGFP-C3 (H) expression plasmids. Numbers indicate the amino acids of Neu1 fused to the C-terminal of FLAG and EGFP. Presented are images of FLAG immunofluorescence using anti-FLAG antibody (A, E, F, G) and direct fluorescence of EGFP fusion proteins (B, C, D, H). - More specifically, A, shows the Neu1-FLAG fusion protein is localized either in the cytoplasm or in the nucleus; B, shows that Neu1/120-EGFP fusion protein containing amino acids 1-120 of Neu1 exhibits constitutive nuclear localization in all cells; C, shows that the Neu1-60/120-EGFP fusion protein is seen exclusively in the nucleus revealing that the first 60 amino acids of NHR1 are sufficient for nuclear localization of Neu1; in D, the Neu1-1/60-EGFP fusion protein containing the N-
terminal 60 amino acids of the brain- specific isoform of m-Neu1 shows localization that is identical to H, localization of EGFP synthesized from the parental pEGFP-C3 expression plasmid; E, inhibition of nuclear export of Neu1-FLAG fusion protein by treatment of Neuro2A cells with leptomycin B (10 ng/ml) for 12 hours or F, 2 days of RA and dBcAMP mediated differentiation leads to predominant nuclear localization of Neu1-FLAG fusion protein; G, FLAG synthesized from parental plasmid is distributed evenly in the cell. - The fusion protein m-Neu1-FLAG comprised of the full-length m-Neu1 with N-terminal FLAG tag showed either predominantly nuclear (˜40% of the positive cells) or predominantly cytoplasmic (˜60% of the positive cells) distribution. If localized in the cytoplasm, m-Neu1-FLAG fusion protein was observed in the form of granular speckles in the perinuclear area, in the vicinity of plasma membrane and in neurites (
FIG. 11A ). - m-Neu1 does not have sequences that are similar to the lysine-rich d-NLS, however, two smaller clusters of arginine and lysine rich amino acids (HKAVKAR (SEQ ID NO: 43) at 80-85 and RLKITKK (SEQ ID NO: 44) at 107-113) are present in the NHR1 of m-Neu1 (
FIG. 1 ). To investigate whether these putative NLSs are functional, the subcellular localization of m-Neu1 deletion mutants fused to the C-terminus of EGFP were analyzed in living cells. Neu-1/120-EGFP fusion protein containing the first 120 amino acids of m-Neu1 displayed nuclear localization in virtually all the cells (100%) (FIG. 11B ). Deletion of the first 60 amino acids from the N-terminal region of m-Neu1 up to the NHR1 domain (Neu-60/120-EGFP) did not change the predominant nuclear localization of the Neu-1/120-EGFP fusion protein (FIG. 11C ). The N-terminal region of Neu1 fused to EGFP (Neu1/120-EGFP) displayed overall cellular distribution of the fusion protein (FIG. 11D ) which was identical to the localization of EGFP (FIG. 11H ). These results showed that the region containing the first 60 amino acids of NHR1 (amino acids 60-120) including two putative NLS domains are sufficient for nuclear import of m-Neu1. - Localization of m-Neu1 fusion proteins in the nucleus and cytoplasm suggest that m-Neu1 transport could be the subject of regulation. Various proteins have been shown to be exported from the nucleus by the CRM1/exportin1-related export pathway that is blocked by the antibiotic leptomycin B (LMB), a specific inhibitor of nuclear export mediated by leucine-rich nuclear export signals (NES). Hood and Silver, Curr Opin Cell Biol, 11:241-247 (1999); Izaurralde and Adam, RNA, 4(:351-364 (1998); Ullman et al., Cell, 90:967-970 (1997); Weiss (1998); Fornerod et al., Cell, 90:1051-1060 (1997); Fukuda et al., Nature, 390:308-311 (1997); Kudo et al., Exp Cell Res, 242:540-547 (1998); Kudo et al., Proc Natl Acad Sci USA, 96:9112-9117 (1999); and Nishi et al., J Biol Chem, 269:6320-6324 (1994). m-Neu1 protein contains two putative leucine-rich sequences, one in the end of each of the NHR (
FIG. 1 ), that are similar to the identified NES in different proteins. Kogerman et al., Nat Cell Bio, 1:312-319 (1999); Taagepera et al., Proc Natl Acad Sci USA, 95:7457-7462 (1998); Ullman et al., Cell, 90:967-970 (1997); and Yamaga et al., J Biol Chem, 274:28537-28541 (1999). In view of these results, the effect of LMB on the localization of m-Neu-FLAG in Neuro2A cells was next studied. - Treatment of Neuro2A cells transfected with m-Neu1-FLAG expression construct with LMB (10 ng/ml) resulted in exclusively nuclear localization of m-Neu1-FLAG at 12 hours post-treatment in virtually all the cells (
FIG. 11E ). These results suggest that m-Neu1 protein shuttles between nucleus and cytoplasm, and that the CRM1/exportin1-related pathway is involved in nuclear export. - Interestingly, the number of cells with nuclear localization of m-Neu1-tagged protein increased substantially (from 45% to 80%) 12 hs after the RA- and cAMP-mediated neuronal differentiation (
FIG. 11F ). It suggests that neuronal differentiation changes the mechanisms that are responsible for the translocation of m-Neu1 protein in Neuro2A cells. - Screening of cDNA libraries and RT-PCR amplification has resulted in isolation of several homologs of mammalian neu1 genes. Polynucleotide sequences of the following homologs are presented as SEQ. ID. NOS.: human neu2 cDNA of SEQ. ID. NO.:21; human neu2 alternatively spliced form h-neu2-ΔNHR1 of SEQ. ID. NO.:23; human neu2 alternatively spliced form h-neu2-ΔNHR2 of SEQ. ID. NO.:25; rat neu2 cDNA SEQ. ID. NO.: 27; human neu3 cDNA of SEQ. ID. NO.: 29; mouse neu3 cDNA of SEQ. ID. NO.: 31; and human neu4 cDNA (partial) of SEQ. ID. NO.: 33. Corresponding peptide sequences are presented as SEQ. ID. NOs: human Neu2 protein of SEQ. ID. NO.: 22; human Neu2 alternatively spliced form h-neu2-ΔNHR1 of SEQ. ID. NO.:24;; human Neu2 alternatively spliced form h-neu2-ΔNHR2 of SEQ. ID. NO.:26; rat Neu2 protein SEQ. ID. NO.: 28; human Neu3 protein of SEQ. ID. NO.: 30; mouse Neu3 protein of SEQ. ID. NO.: 32; and human Neu4 protein (partial) of SEQ. ID. NO.: 34. All the mammalian Neu proteins show significant homology in the NHR and Ring zinc finger domains.
- Alignment of neuralized homology motifs of human Neu1, Neu2, and Neu3 proteins is shown in
FIG. 12 . Amino acid sequence comparison of the neuralized homology regions (NHR) of Drosophila neu and human neu1, neu2 and neu3 proteins is shown inFIG. 12 . Amino acids that are identical in human and Drosophila neu proteins are highlighted in white on black background. Amino acids that are similar in human and Drosophila neu proteins are boxed and highlighted on grey background. h1I, NHR1 of human neu1; h2I, NHR1 of human neu2; h3, NHR of human neu3; dI, NHR1 of Drosophila neu; dII, NHR2 of d-neu; h1II, NHR2 of human neu1; h2II, NHR2 of human neu2. - Expression of neu1 mRNA is highest in adult, mature neurons (
FIG. 2-7 ). neu2, in contrast to neu1, is expressed at high levels already in the embryonic brain and the expression levels decrease during postnatal development (FIG. 13 ). Total RNA was isolated from the indicated mouse and rat brain regions and non-neural tissues and the levels of neu2 transcripts were analyzed by RNase protection assays. cRNA probes that were used for detection of neu2 transcripts covered the region encoding the NHR1 of rat neu2. Specific protected fragments are indicated on the left of the panel. R-NEU2, rat neu2 transcript; M-NEU2, mouse neu2 transcript. E, Embryonic day; P, postnatal day; ad, adult; HC, hippocampus; CTX, cerebral cortex; OLF, olfactory bulb; STR, striatum; THA, thalamus; HTH, hypothalamus; COL, colliculi; MID, ventral midbrain; CBL, cerebellum; PONS, pons; MED, medulla;SP.C, spinalcord; PIT, pituitary; MUS, muscle; SPLCE, spleen tRNA, yeast tRNA as a negative control. - neu3 is widely expressed, with highest levels in immune tissues spleen and thymus, and in the lung (
FIG. 14 ). Total RNA was isolated from the indicated mouse brain regions and non-neural tissues and the levels of neu3 transcripts were analyzed by RNase protection assays. cRNA probes that were used for detection of neu3 transcripts covered the region encoding the NHR of mouse neu3. Specific protected fragments are indicated on the left of the panel. E, Embryonic day; P, postnatal day; AD, adult; HC, hippocampus; CTX, cerebral cortex; OLF, olfactory bulb; STR, striatum; THA, thalamus; COL, colliculi; MID, midbrain; CBL, cerebellum; PONS, pons; MED, medulla; LIV, liver; HEA, heart; KID, kidney; LUN, lung; MUS, muscle; SPL, spleen; TES, testis; THY, thymus; tRNA, yeast tRNA as a negative control. - Expression of neu4 was detected only in muscle and heart.
- An adult rat brain library was screened using a yeast two hybrid system with a mouse Neu1 protein as a ligand with which to isolate and identify proteins that interact with Neu1. Fifty-three (53) clones were isolated. cDNAs that yielded more than 1 clone were sequenced and identified as four interactors: NeuI-1, NeuI-2, NeuI-3, and NeuI-4.
- Sequence analyses showed that all interactors were novel proteins and contain RING finger domain located in the C-terminus of the protein. NeuI-1 (4 clones) is a novel splice variant (SEQ. ID. NO.: 29) of zinc finger protein Miz1/PIASX/ARIP3 (GenBank accession number NM—008602; AF077953; AF077954; AF044058). NeuI-2 (3 clones) is a fourth homologue (SEQ. ID. NO.: 30; GenBank accession number AF277171; AF302084) of zinc finger protein ZNF127 (GenBank accession number U19106; U19107), NeuI-3 (9 clones) has highest homology to a human hypothetical protein (GenBank accession number AK001459) and to a Drosophila hypothetical protein (AAF56052.2) produced from CG4813 gene of a genomic scaffold (GenBank accession number AE003740) (SEQ. ID. NO.: 31), and NeuI-4 (12 clones) is the homologue of the androgen receptor co-activator ARA54 (SEQ. ID. NO.: 32; GenBank accession number AF060544).
- Expression of neuI-1-neuI-4 mRNAs was analyzed in developing and adult rat brain and non-neural tissues (
FIG. 15 ). Total RNA was isolated from the indicated rat tissues and the levels of transcripts were analyzed by RNase protection assays with cRNA probes specific for NeuI-1, NeuI-2, NeuI-3 and NeuI-4 transcripts. Specific protected fragments are indicated on the left of each panel. Bottom panel shows the levels of GAPDH mRNA in the RNA samples. E, Embryonic day; P, postnatal day; ad, adult; cbl, cerebellum; ctx, cerebral cortex; stem, brainstem; hc, hippocampus; hc+KA, hippocampus from rats treated for 4h with the glutamate receptor agonist kainic acid; hea, heart; kid, kidney; mus, skeletal muscle; spl, spleen; thy, thymus; tes, testis; li, liver; lu, lung; tRNA, yeast tRNA as a negative control. - All the identified Neu1 interactors were expressed in the brain and skeletal muscle, tissues where neu1 mRNA is predominantly expressed. This suggests that neuI-1-neuI-4 interact with
Neu 1 protein and modify its activity in vivo. - The function of Neu1 as a calcium-dependent transcriptional repressor was studied by transfecting Neuro2A cells with m-neu1-CMV expression vector. This system was used to examiner whether or not Neu1 could suppress transcription of IEGs in response to the simultaneous stimulation of cells with calcium, ionophore A23187, and forskolin. As a combination of forskolin with calcium, ionophores leads to increased c-fos mRNA levels in Swiss 3T3 cells (Mehmet H, 1990). Because the induction of immediate early genes by Ca2+ influx requires cAMP-dependent protein kinase in PC12 cells (Ginty DD, 1991), it was decided to apply the forskolin and ionophore co-treatment to Neuro-2A cells.
- Upon transient transfection of m-Neu1 into Neuro2A cells, activation of transcription of several IEGs (c-fos, junB, junD, c-jun, fra-1, and fra-2) from their endogenous promoters was significantly reduced in response to the raised intracellular Ca2+ (Ca ionophore) and cAMP activity (forskolin) levels. Neu1 elevated levels affected the amplitude of the IEG mRNA induction, however, had no effect on the time course of induction. This finding couples Neu1 to stimulus (calcium)-dependent transcriptional regulation.
- Because m-Neu1 affects a variety of target gene promoters in transient transfection assays, it was hypothesized that m-Neu1 functions by interfering directly with the function of Pol II complex, particularly suppressing the TBP transcriptional activity. To examine this possibility, m-Neu-CMV expression constructs were cotransfected together with m-TBP-CMV. The effect of this procedure on thymidine kinase (tk) promoter was examined. Increasing amounts of Neu-CMV while mTBP-CMV amounts were kept constant (and vice versa) resulted in the decreased activity of the reporter gene in Neuro2A cells. These results suggested that m-Neu1 could repress transcription by direct interaction with TBP.
- A biopsy is obtained from a subject possibly suffering from a neoplastic disease, such as an astrocytoma. Following excision of the sample, the tissue is immediately minced and quickly frozen in liquid nitrogen. A
sample 1 gram sample of tissue is then ground with a prechilled mortar and pestle for suspension. The ground tissue is then suspended in approximately 1.2 ml of digestions buffer (100 mM NaCl, 10 mM Tris-Cl, pH 8.0, 25 mM EDTA, pH 8.0, 0.5% (w/v) SDS, and 0.1 mg/ml proteinase K, which is added fresh for each use). Samples are shaken and incubated for 12 to 18 hours at 50° C. - Following the incubation period, the samples are extracted with an equal volume of phenol/chloroform/isoamyl alcohol, to remove proteinatious material. Centrifuge the mixture for 10 minutes at 1700×g. If phases do not resolve well, add another volume of digestion buffer, omitting proteinase K, and repeat centrifugation. Repeat the extraction until no thick white material appears at the interface. Transfer the top aqueous layer to a new tube.
- To this tube is added ½ volume of 7.5 M ammonium acetate and 2 volumes of 100% ethanol. This mixture is centrifuged for 2 minutes at 1700×g. Following the centrifugation, the resulting pellet is washed with 70% ethanol, and then air dried and will be resuspended in Tris-EDTA buffer at approximately 1 mg/ml.
- To prevent shearing of high molecular weight DNA it may be advisable to remove organic solvents and salt by two dialyses against 100 volumes of Tris-EDTA buffer for more than 24 hours. If this step is performed, the pellet is not resuspended in Tris-EDTA buffer.
- The purified DNA is analyzed for the presence or mutation of a wild type copy of a neu family gene using Southern Blotting and sequencing. The absence or mutation of such in the subject indicates the presence of a malignancy.
- A tissue sample is obtained from a subject possibly suffering from a neoplastic disease. The biopsy is removed and cut into less than 2 gram pieces. These pieces are quick-frozen in liquid nitrogen. Twenty (20 ml) of tissue guanidinium solution is used to process 2 grams of tissue. The tissue guanidinium solution is prepared by dissolving 590.8 grams of guanidinium isothiocyanate in approximately 400 ml DEPC-treated H2O. To this is added 25 ml of 2M Tris-Cl, pH 7.5 (0.05 M final) and 20 ml of 0.5 M Na2EDTA, pH 8.0 (0.01 M final). Stir overnight, adjust the volume to 950 ml, and filter. Finally, add 50 ml 2-ME.
- Once the tissue guanidinium solution is added to the tissue, the sample is immediately ground in a tissuemizer with two or three ten second bursts. Following disruption, the solution is subjected to centrifugation for 10 minutes at 12,000×g in a SS-34 rotor, at 12° C. To the supernatant is added 0.1 volumes of 20% Sarkosyl. This mixture is then subjected to heat at 65° C., for 2 minutes.
- To this heated solution is added 0.1 grams of CsCl/ml of solution, which is mixed until it dissolves. The sample is next layered over 9 ml of 5.7M CsCl in silanized and autoclaved SW-28 tubes. These tubes are centrifuged overnight at 113,000×g in a SW-28 rotor at 22° C.
- Following the centrifugation step, the supernatant is removed and the tubes are inverted to drain. The bottom of each tube is removed and the RNA pelleted contained therein is placed in a 50-ml plastic tube. Three (3) ml of tissue resuspension buffer and allow pellet to resuspend overnight or longer at 4° C. Extract solution sequestially with 25:24:1 phenol/chloroform/isoamyl alcohol, then with 24:1 chloroform/isoamyl alcohol. Add 0.1 volume of 3 M sodium acetate, pH 5.2, and 2.5 volume of 100% ethanol, precipitate, and resuspend RNA in water. The sample is quantitated and analyzed for the expression of the neu family of genes. Samples with aberent expression levels indicate the presence of neoplastic cells.
- Cells are isolated from a subject to be transfected with a construct encoding Neu protein (Neu construct). The Neu construct is transfected using DEAE-dextran. The cells are seeded in 6-well tissue culture plates and are transfected with a total of 1-2 μg of total DNA containing the Neu contruct. After 5 hours, 1 ml of DMEM containing 20% fetal bovine serum is added and the cells are allowed to incubate overnight.
- Expression of Neu is then determined using immunoprecipitation with an antibody-agarose conjugate (8 μg) plus 25 μl of a 50% slurry of Protein A-agarose. Immune complexes are washed in a wash buffer (20 mM Hepes, pH 7.4, 10 mM MgCl2, and 1 mM DTT). The immune complexes are placed in a denaturing protein sample buffer that separated the antibody from any bound antigen. The protein samples are then run on SDS-polyacrylamide gel electrophoresis to detect the expression of a target Neu protein.
- The foregoing description details certain embodiments of the invention. It will be appreciated, however, that no matter how detailed the foregoing appears in the text, the invention can be practised in many ways. Although this invention has been described in terms of certain preferred embodiments, other embodiments which will be apparent to those of ordinary skill in the art in view of the disclosure herein are also within the scope of this invention. As is also stated above, it should be noted that the use of particular terminology when describing certain features or aspects of the invention should not be taken to imply that the terminology is being re-defined herein to be restricted to include any specific characteristics of the features or aspects of the invention with which that terminology is associated. Accordingly, the scope of the invention should therefore be construed in accordance with the appended claims and any equivalents thereof.
Claims (8)
1-30. (canceled)
31. A purified neuralized (Neu) polypeptide, comprising at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain, wherein said Neu polypeptide has at least 90% sequence identity to SEQ ID NO:22 and is capable of suppressing transcription.
32. The purified Neu polypeptide according to claim 31 , wherein said Neu polypeptide has at least 95% sequence identify to SEQ ID NO:22.
33. The purified Neu polypeptide according to claim 31 , wherein said Neu polypeptide comprises SEQ ID NO:22.
34. The purified Neu polypeptide according to claim 31 , wherein said neuralized homology repeat domain comprises SEQ ID NO:48.
35. An antibody capable of specifically binding to an isolated Neu polypeptide according to claim 31 .
36. The antibody according to claim 35 , wherein said antibody specifically binds to a polypeptide comprising at least 10 consecutive amino acids of said Neu polypeptide.
37. The antibody according to claim 35 , wherein said antibody is a monoclonal antibody.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/125,970 US20060160103A1 (en) | 2001-03-14 | 2005-05-09 | Mammalian neuralized family transcriptional regulators and uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/808,387 US6962985B2 (en) | 2001-03-14 | 2001-03-14 | Mammalian neuralized family transcriptional regulators and uses therefor |
US11/125,970 US20060160103A1 (en) | 2001-03-14 | 2005-05-09 | Mammalian neuralized family transcriptional regulators and uses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/808,387 Continuation US6962985B2 (en) | 2001-03-14 | 2001-03-14 | Mammalian neuralized family transcriptional regulators and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060160103A1 true US20060160103A1 (en) | 2006-07-20 |
Family
ID=25198619
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/808,387 Expired - Fee Related US6962985B2 (en) | 2001-03-14 | 2001-03-14 | Mammalian neuralized family transcriptional regulators and uses therefor |
US11/125,970 Abandoned US20060160103A1 (en) | 2001-03-14 | 2005-05-09 | Mammalian neuralized family transcriptional regulators and uses |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/808,387 Expired - Fee Related US6962985B2 (en) | 2001-03-14 | 2001-03-14 | Mammalian neuralized family transcriptional regulators and uses therefor |
Country Status (5)
Country | Link |
---|---|
US (2) | US6962985B2 (en) |
EP (1) | EP1409508A4 (en) |
AU (1) | AU2002247302A1 (en) |
CA (1) | CA2455413A1 (en) |
WO (1) | WO2002072767A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7265202B1 (en) * | 1997-11-28 | 2007-09-04 | The Regents Of The University Of California | PIAS molecules that recognize and bind STAT proteins and uses thereof |
US20040219575A1 (en) * | 2002-12-26 | 2004-11-04 | Toomas Neuman | Methods and compositions for the diagnosis, prognosis, and treatment of cancer |
SG11201901265SA (en) * | 2015-07-21 | 2019-03-28 | Univ Jefferson | Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JPH11137257A (en) | 1997-11-14 | 1999-05-25 | Sumitomo Electric Ind Ltd | Neuralized protein, polynucleotide encoding the protein and antibody recognizing the protein |
US6294328B1 (en) * | 1998-06-24 | 2001-09-25 | The Institute For Genomic Research | DNA sequences for strain analysis in Mycobacterium tuberculosis |
-
2001
- 2001-03-14 US US09/808,387 patent/US6962985B2/en not_active Expired - Fee Related
-
2002
- 2002-03-08 CA CA002455413A patent/CA2455413A1/en not_active Abandoned
- 2002-03-08 WO PCT/US2002/007201 patent/WO2002072767A2/en not_active Application Discontinuation
- 2002-03-08 EP EP02715083A patent/EP1409508A4/en not_active Withdrawn
- 2002-03-08 AU AU2002247302A patent/AU2002247302A1/en not_active Abandoned
-
2005
- 2005-05-09 US US11/125,970 patent/US20060160103A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020132293A1 (en) | 2002-09-19 |
AU2002247302A1 (en) | 2002-09-24 |
US6962985B2 (en) | 2005-11-08 |
WO2002072767A3 (en) | 2003-03-06 |
WO2002072767A2 (en) | 2002-09-19 |
CA2455413A1 (en) | 2002-09-19 |
EP1409508A4 (en) | 2005-05-11 |
EP1409508A2 (en) | 2004-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fan et al. | Expression Patterns of Two Murine Homologs ofDrosophila Single-MindedSuggest Possible Roles in Embryonic Patterning and in the Pathogenesis of Down Syndrome | |
US6379925B1 (en) | Angiogenic modulation by notch signal transduction | |
JP5480488B2 (en) | Soluble inhibitors of vascular endothelial growth factor and uses thereof | |
Montolio et al. | A semaphorin 3A inhibitor blocks axonal chemorepulsion and enhances axon regeneration | |
JP2002514055A (en) | DNA encoding galanin GALR3 receptor and use thereof | |
JP2010047588A (en) | Gene encoding new transmembrane protein | |
KR100227240B1 (en) | The ciliary neurotrophic factor receptor | |
EP0960937B1 (en) | Novel semaphorin gene: semaphorin y | |
US20060160103A1 (en) | Mammalian neuralized family transcriptional regulators and uses | |
JP3112936B2 (en) | Polypeptides having dopamine receptor activity, nucleic acids encoding these polypeptides and the use of these polypeptides to screen for substances active against these polypeptides | |
JP2006511194A (en) | Teneurin C-terminal related peptide (TCAP) and methods and uses related thereto | |
US6432410B1 (en) | Morphogenic proteins | |
JPH06507062A (en) | ciliary neurotrophic factor receptor | |
JP4011629B2 (en) | Novel semaphorin gene (I) | |
US6902730B1 (en) | Semaphorin gene: Semaphorin W | |
US20030013087A1 (en) | Novel mutations in the freac3 gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis | |
US7749758B2 (en) | Human and mammalian stem cell-derived neuron survival factors | |
JP2002540765A (en) | Novel protein | |
JP2002530104A (en) | Potassium channel interactors and uses thereof | |
US7056667B2 (en) | Spatial learning and memory | |
US6268216B1 (en) | Reagents and methods for the screening of compounds useful in the treatment of neurological diseases | |
US20030175830A1 (en) | Reagents and methods for the screening of compounds useful in the treatment of neurological diseases | |
JPH09238685A (en) | Cerebral ischemia-related gene | |
JPWO2004001038A1 (en) | Novel genes and proteins involved in neuronalization of cells or tissues and use thereof | |
JP2005006542A (en) | New gene alivin 1 participating in existence of neurocyte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CEMINES RESEARCH LLC, COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PALM, KAIA;TIMMUSK, TONIS;REEL/FRAME:019106/0224;SIGNING DATES FROM 20010531 TO 20010604 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |